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1Jane Calvert
Engineering Life
This workshop on the history of DNA syn-
thesis was one of a series of interdisciplinary 
workshops organised by the Engineering Life 
project. The project investigates the move-
ment of ideas, practices, policies and promises 
from engineering into the life sciences. Its fo-
cus is on synthetic biology, a field that aspires 
to engineer biological systems. Although DNA 
synthesis is essential to synthetic biology, it often remains in the back-
ground in discussions of the field. By bringing it to the foreground this 
workshop contributed to the Engineering Life project in several ways. 
Importantly, it provided a new way of thinking about the history of 
synthetic biology, which often traces its origins to the early 2000s, 
when its engineering agenda was articulated. Focusing on synthesis 
allowed us to connect synthetic biology to a much longer trajectory of 
DNA synthesis, starting in the 1950s. The workshop also highlighted 
the importance of chemistry, alongside biology and engineering, in 
DNA synthesis and in synthetic biology more broadly. It also raised 
challenging questions about the differences between synthesized and 
non-synthesized DNA; about the importance of provenance, inherit-
ance and genealogical relationships, and what happens when these 
are bypassed by chemical DNA synthesis. Relatedly, thinking about 
the distinctiveness of synthesized DNA drew our attention to the na-
ture of DNA itself. Synthesis produces a material entity, a molecular 
sequence, but DNA is more than this in also being a carrier of infor-
mation and a product of evolution. By foregrounding these historical 
and conceptual dimensions of DNA synthesis the workshop allowed 
us to think afresh about current large-scale whole genome synthesis 
projects involving yeast and human genomes. Finally, I would like to 
say how valuable it was to hold the workshop at the Science History In-
stitute, where the unique historical expertise in chemistry, engineer-
ing and the life sciences greatly enriched our discussions.
Introduction from Engineering Life 
and the Science History Institute
2Jody Roberts
Science History Institute
The Science History Institute was proud to 
partner with the Engineering Life project 
team at University of Edinburgh to make this 
unique workshop possible. At the core of our 
institution’s mission is creating tools to make 
the past accessible in ways that can foster im-
portant conversations across constituencies 
about the place of science in our society. As 
the Chemical Heritage Foundation has morphed into the Science His- 
tory Institute following its merger with the Life Sciences Foundation, 
we are particularly excited about occasions for highlighting and exam- 
ining the connected histories of these molecular fields. The history of 
DNA synthesis provides an almost perfect exemplar for charting out 
new directions for collections, knowledge production, and public en- 
gagement about these critical breakthroughs that continue to impact 
all of our lives.
The workshop focused on an often forgotten or overlooked aspect of 
laboratory science: the role of new instrumentation as a driving force 
for breakthroughs. The presentations and conversations at this work- 
shop traced the ways in which laboratory technique becomes codified 
in an instrument; how the commercialization of an instrument trans- 
fers skills and capabilities to users across new geographies; and how 
this mobilization of users yields the sort of breakneck breakthroughs 
that have come to define contemporary discourse in and about syn- 
thetic biology and biomedical research. By convening a group of practi- 
tioners, observers, and researchers from fields in and around 
synthetic biology, we simultaneously captured the before and after 
moments of instrumental development and caught a glimpse of how 
this technology continues to shape how and where research is 
done, what questions can be explored, and what might become 
possible in a not too distant future. In settings such as this it’s natural 
to ask the question: how will this history be preserved? We were 
delighted to facilitate a process of discovery connecting our museum 
at the Science History Institute to the participants of this workshop 
to begin what is always a long process of imagining and then 
initiating a collecting initiative that can serve as a representative 
collection of this work. On behalf of the Science History Institute, I 
am delighted to have had the opportunity to collaborate with the 
Engineering Life project. Their work has created an uncommon 
space for thoughtful deliberation, inspection, and perspective 
needed for finding aligning emerging science with social needs.
3This workshop attended to the ways in which methods for the chemi-
cal synthesis of organic materials has mattered, and continues to mat-
ter, for biological science and technology. It adopted a fundamentally 
historical approach with a focus on the synthesis of DNA, and was 
informed by accounts from scientific practitioners, social scientists, 
museologists, philosophers, and historians. The workshop’s investiga-
tion was inspired by a focal point: the efforts of a small international 
community of scientists and engineers who from around the 1960s 
picked up the challenge of synthesizing nucleotide sequences with-
out having to rely on finding desired sequences in existing organisms. 
This was the making of sequences through chemistry, technology and 
engineering. While the historiography of biotechnology is vast, the 
capacity for DNA synthesis itself has largely gone unnoticed, the vast 
majority of work focusing on techniques for recombination, its mean-
ings, broader social significance, and reception amongst diverse pub-
lics. By staying focussed on the particularities of biological molecules 
as synthesised the workshop aimed to break new ground, drawing in 
material culture, engineering studies, and their historical, philosophi-
cal and sociological intersections. 
While DNA synthesis was the focal point, these activities needed to 
be understood in a longer and broader context, right up to the present. 
Speakers accordingly focussed on a range of periods, and highlighted 
different features when it came to synthesis and the organism, each 
with an emphasis on different kinds of scientific, commercial, or or-
ganic actor. Indeed it is no doubt thanks to the diversity of the kinds of 
actor involved that scholars in the history of science have yet to grap-
ple with the cases addressed here, the majority staying within either 
chemistry, biology, or engineering. This workshop recognises that 
synthesis sits in an uncomfortable research space for historians and 
philosophers of science. It was dedicated to addressing this discomfort 
and producing materials for the systematic international investigation 
of nonbiological, or perhaps ‘mechano-chemical’ DNA synthesis, the 
philosophical questions it provokes, the historiographical revisionism 
it invites, and the social relations it changes.
Executive Summary
4Part 1 of the report incorporates short summaries of the papers given 
(each of which was 20 minutes in length) and reports of the question 
period. Part 2 includes the biographies of our participants. In an annex 
we include copies of the workshop documentation. For the author of 
the report the following themes seem to deserve particular attention:
1. Decomposition and recomposition
At various different points in the history of science, experimenters 
have been prompted to celebrate the strategy of repeated rounds of 
analysis and recombination, followed by further analysis and further 
recombination. In biology for instance we might think of William 
Batesons’ analogies between decomposition and recomposition in 
chemistry and the same practices in genetics, or Wilhelm Johannsen’s 
emphasis on the usefulness of composing and decomposing pure lines 
to understand heredity. From a very abstract perspective, one devoid 
of any specific experimental content, it can be difficult to distinguish 
between all the different kinds of epistemic strategy that marry to-
gether induction and intervention in this way. For instance, is there 
anything additional implied by the ‘bottom-up’ approach in minimal 
cell research, or the ‘design, build, test’ cycle emphasised in synthet-
ic biology, beyond Francis Bacon’s sixteenth century commitment to 
combining ‘works of fruit’ with ‘works of light’? The extreme and ahis-
torical nature of this juxtaposition is intended to puncture much of 
the inflationary rhetoric used by present proponents of particular ex-
perimental designs.  
What we learn from the papers presented in this workshop, is that 
arguments about the epistemic value of decomposition and recom-
position must first be made meaningful through the specifics of the 
material being decomposed and recomposed. A focus on the specifics 
of DNA, what it does, where it comes from, its various roles in experi-
mentation and analysis, is a methodological commitment that also al-
lows us to analyse and assess broader experimental designs and epis-
temic strategies that are argued to relate to them. Obviously this kind 
of methodological commitment can be extended to materials well be-
yond DNA.
2. Values and value making
Throughout the workshop different speakers made different claims as 
to what things were valuable, or became valuable, and introduced dif-
ferent kinds of value, from financial, to social, experimental, moral, 
and many things in between. The making of DNA and its becoming 
an experimental commodity is therefore at one and the same time a 
5history of making values. In this respect the history of DNA synthesis 
can be immediately related to ongoing research on values and valu-
ation, historical interpretation of the relations between science and 
technology and economic change, public and private property, intel-
lectual property, and cultures of innovation.
Remembering that different stakeholders will have different concep-
tions of what is valuable, and what can be valuable, provides excellent 
grounds for the motivation of historical research and analysis. Indeed 
a communities’ responding to and learning how to value material-
semiotic objects is often at the heart of an historical enquiry. Being 
explicit about this opens up interdisciplinary paths between historical 
and social scientific research, while providing richer materials for his-
tories of the sciences. It also further emphasises the need to draw in a 
wide range of stakeholders, including scientists, industrialists, econo-
mists, social historians, civil society, and so on, all of whom will have 
their own views as to what is valuable, most valuable, and why.
Fig. 1. Left to right: Dr. Jody Roberts (Director of Science History Institute’s Institute for Research and 
managing director of SHI); Dr. Dominic Berry (Research Fellow, Engineering Life Project); Marv Caru-
thers (Distinguished Professor of Biochemistry and Chemistry at the University of Colorado, Boulder 
and pioneer in DNA synthesis); Dr. Robert G. W. Anderson (President and CEO of Science History Insti-
tute), in the biochemistry and biotechnology section of the SHI museum. Thanks to Samantha Blatt of 
the SHI for taking this photograph and thanks to the SHI for permission to use it.
63. The history of biology meeting the history of technology
The intersection of the history of biology and history of technology 
has been subject to considerable renewed attention in recent years. At 
present historians trained in each subject are increasingly learning 
how to apply their historiographical approaches to cases thought to lie 
outside their primary, perhaps even appropriate, research contexts. 
DNA synthesis provides an ideal case study for those contributing to or 
skeptical of this agenda, for it is impossible to tell its history without 
addressing biology and technology (and chemistry and engineering) 
simultaneously. How historians can and should respond to these kinds 
of context is currently being debated, and DNA synthesis can provide 
a range of provocations. 
To different people DNA is an experimental tool, epistemic object, 
commodity, chemical and physical and biological material, natural 
resource, economic resource, political arena, and many more other 
things that we commonly only research through attention to its re-
combination. By attending to the fact that there are different methods 
for the making of DNA, we can grasp the different meanings of its mak-
ing, and revise history accordingly.
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8Summaries of Workshop Presentations
This workshop constitutes part of the 
Engineering Life project, which is run by 
Prof. Jane Calvert in Edinburgh. We are 
an interdisciplinary team of researchers, 
including social scientists, geographers, 
historians, all of us with quite different 
backgrounds, dedicated to researching 
contemporary science as it is practiced in 
the present. The broad umbrella that we 
are interested in is biological engineering, 
and within that, we are particularly inter-
ested in studying synthetic biology: trying 
to understand what’s going on with that 
range of sciences, the developments un-
derway, and the ways in which it is signifi-
cant for broader society. For myself, as a 
historian of science, my role on the project 
is to try and historicize contemporary sci-
ence, to try and bring history to synthetic 
biology, and in the process bring the value 
of the history and philosophy of science 
to the present. For me that is all that this 
Session 1: Introduction to the Worskhop
Fig. 2. Model of the Structure of Penicillin, by Dorothy Hodgkin. By Museum of the History of Science, 
University of Oxford [CC BY-SA 3.0], via Wikimedia Commons.
Dominic Berry
Introduction
9workshop is made of and dedicated to, try-
ing to explore the past in order to better 
understand and appreciate the present. 
One important thing to recognise about 
our workshop today is that it is deeply 
interdisciplinary. We have people from a 
whole range of backgrounds, interests, 
expertise, their own reasons for finding 
something like DNA synthesis interesting. 
That interdisciplinarity is important for 
at least two reasons. One, the phenomena 
that we are all here to discuss, DNA syn-
thesis, is itself a deeply interdisciplinary 
phenomena. There were lots of kinds of 
actor involved, and lots of different exper-
tise involved. Another reason to make this 
an interdisciplinary event, is that there is 
lots to do! We need as many people as we 
can get in order to pool together this his-
tory. So I hope from our discussions we can 
learn what kinds of institutions we want to 
go and investigate further, which archives 
to try and find, which people to try and fol-
low up, who we need to convince to leave 
their papers to an archive, to build the ar-
chive that we need. Another question that 
is close to the heart of the Science His-
tory Institute, is what kinds of objects we 
might want to collect in order to preserve 
the material history of something like 
DNA synthesis. I am hoping we can get lots 
of ideas here. When you take a topic like 
DNA synthesis, we have the opportunity 
to think large and be ambitious about what 
we want to do with that history. 
Not everyone here is used to thinking 
historically, and those of you that are, we 
don’t all think historically in the same way. 
So with the rest of my introduction I want 
to give you an insight into how I, myself, 
understand historical change, and the 
kinds of history that I see today contrib-
uting to. Not so that I can convince you it’s 
the right one, but so you can appreciate 
some of the quirkier aspects of the work-
shop. In order to do that I am going to lean 
on an analogy from the history of x-ray 
crystallography. 
When Dorothy Hodgkin was working on 
the structure of penicillin, she adopted the 
practice in x-ray crystallography, of map-
ping out the data on sheets of perspex. 
These would then be layered one on top of 
another, allowing you to look through the 
perspex, eventually coming to appreci-
ate what the 3D structure must look like. 
I think this helps as analogy to visualise 
my understanding of historical change. 
But what are we trying to understand the 
structure of, what is our penicillin?
There are some interesting questions 
about how to actually describe the topic 
of our workshop. Is DNA synthesis right? 
I have proposed mechano-chemical in the 
workshop proposal, in order to recognise 
the variety of features that make this kind 
of synthesis distinct from what is going on 
in cells, but what do you think of that? For 
lots of purposes today we are going to be 
able to say synthesis or chemical synthesis, 
but does that capture everything going on 
in those instantiations, and are there oth-
er interpretations? It’s also the case that 
perhaps we are actually wanting to talk 
about something else, and the synthesis 
frame ultimately does not work. One could 
have easily organised todays workshop 
around ‘model organism research and bio-
tech’, with DNA synthesis becoming one 
amongst a number of technologies that 
mattered, or we could have gone for ‘histo-
ries of the commercialisation of university 
research’, and again DNA synthesis would 
have become one of a number of examples.
Why chose DNA synthesis then? Well 
if you’re part of a project focussed on syn-
thetic biology, then DNA synthesis is a 
very quick way to start forcing some his-
tory into contemporary practices, because 
synthesis is essential to everything that 
synthetic biologists get up to. So if we 
can learn more about the history of DNA 
synthesis we are de facto learning about 
the history of synthetic biology, even if it 
is not necessarily on the historical terms 
that synthetic biologists understand them-
selves. Another reason to choose this focus, 
is that in terms of the history of biotech-
nology, DNA synthesis has been neglected, 
even though it does come into parts of sto-
ries that are very well known, such as the 
The history of DNA synthesis is at one and 
the same time chemical, biological, tech-
nological, and engineered
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Human Genome Project or PCR. DNA syn-
thesis has not had this kind of dedicated 
attention that we’re going to give it today. 
The time is ripe for people to start doing so, 
drawing in people who have been working 
in fields associated with DNA synthesis, 
and start collecting the materials that we 
would need in order to preserve it. Lastly, 
I think this approach to  the topic sets us 
up with some nice historiographical chal-
lenges. The history of DNA synthesis is at 
one and the same time chemical, biologi-
cal, technological, and engineered. As good 
as the discipline of the history of science 
is, it is not necessarily good yet at dealing 
with that kind of historical space. So an-
other reason to have this workshop is to 
produce materials that will make such an 
exploration easier for other historians in 
the future. 
Returning now to Hodgkin, I want us to 
be thinking of those perspex sheets, lay-
ered on top of one another, and the over-
all structure that emerges, as we try and 
piece together a history of DNA synthe-
sis. We are perhaps trying to find ways to 
perform x-ray crystallography on the past, 
at least, that is an image that feels right, 
to my mind, as being close to what it is to 
think historically about a subject. Some of 
the parts of the structure will be directly 
connected, other parts disconnected, other 
parts meeting for a while before going off 
to have lives of their own. But you come to 
grasp the whole by putting everything into 
place. 
Session 1: Whole genomes / organisms
What do synthesis experiments add to our 
understanding and our capacity to explain 
things? How new kind of work do synthe-
sis experiments do? Similarly, a parallel 
question is what do synthesis experiments 
add to technology and how do they do it? 
In this paper, I focus on a particular class 
of synthesis experiments called Total Syn-
thesis projects. I will discuss two cases and 
in both of them, I will use the standards 
of total synthesis projects as practiced by 
chemists to elucidate their contributions.
The Nobel Prize-winning chemist Gob-
ind Khorana highlighted the integrative 
nature of working on chemical experi-
ments in biology in the opening sentence 
of his Nobel lecture: “Recent progress in 
the understanding of the genetic code is 
the result of the efforts of a large number 
of workers professing a variety of scien-
tific disciplines.” (He received the prize 
in 1968 for his work on “interpretation of 
the genetic code and its function in protein 
synthesis.) For myself what matters here 
is the idea of individual researches pro-
fessing and practicing a range of scientific 
disciplines and thereby synthesizing those 
disciplines. 
I will be arguing that synthesizing does 
more than explaining; explaining and 
making both develop capacities for pulling 
systems apart and putting them back to-
gether; and that making is more than ma-
nipulating. When it comes to making the 
chemist holds a different standard than the 
one that biologists have typically adopted. 
That making is more than manipulating 
and is a way to reconcile two different kinds 
of complexities: descriptive complexity, 
and interactive complexities. By descrip-
tive complexity, I mean that explanations 
and mechanisms delineated in the same 
phenomena by different disciplines do not 
easily coincide. For example, for the gene, 
the informational picture, the chemical 
biosynthetic picture, and the physiologi-
cal picture don’t line up by themselves—
like Dorothy Hodgkin’s perspex sheets do. 
By interactive complexity, I mean that the 
explanations and mechanisms work across 
multiple dimensions of explanation. For 
example, the chemi-synthetic picture of 
the gene is only a subset of the full pheno-
type generating aspect of the physiological 
gene referred to by the geneticists. These 
descriptions and explanation can line up in 
Alok Srivastava & Elihu M. Gerson
Synthesis of Viable Genomes and Organisms: Understanding Wholes
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Making is more than manipulating and is 
a way to reconcile two different kinds of 
complexities: descriptive complexity, and 
interactive complexities.
practice if the independent diagrams we 
hold bring you to do something new in the 
lab, but those diagrams themselves can’t 
line up one on top of each other to be part 
of the same whole.
Before I begin, I also need to explain 
the particular standing of total synthesis 
experiments and projects in contrast to 
synthesizing a part of a whole or demon-
strating the mechanistic operation of a 
part. Experiments demonstrating the com-
plete chemical synthesis of biologically vi-
able wholes such as genes and genomes 
are examples of Total Synthesis experi-
ments. Total synthesis projects are a long-
standing institution in the professional 
world of chemists and have been adopted 
subsequently by biochemists, molecular 
biologists and most recently by synthetic 
biologists. This has been applied to DNA, 
biosynthetic pathways, biochemical com-
plexes, genes, regulatory pathways, and 
now genomes, with the hope of getting to 
organisms. One of the points of the talk is 
to distinguish the claim of synthetic organ-
isms versus synthetic genomes. What this 
synthesis means is different according to 
the type of scientist involved. Biochemists 
hold themselves to having reconstituted 
purified components that comprise DNA 
polymerase activity or RNA polymerase 
activity. Molecular and cell biologists they 
reconstitute complexes in vivo. And syn-
thetic biologists are taking it to recompose 
whole systems.
In this talk, we also want to introduce 
two distinct types of coordinative arrange-
ments entailed by the work of assembling 
parts into viable wholes—scaffolds to hold 
the organization of parts while under con-
struction and brackets to hold together 
parts or capacities that are not linked but 
must operate near each other.
I will be working with two cases of total 
synthesis projects. First is the accomplish-
ment in 1979 of the Khorana lab demon-
strating the first total synthesis of a gene 
and showing its biological activity. The 
other is the claim from March 2016 of the 
total synthesis of a minimal genome—they 
are careful to avoid saying ‘organism’, but 
do the chemist’s standards of total syn-
thesis projects allow such a distinction 
between the material entity and its biolog-
ical behaviour? The Khorana lab success-
fully demonstrated a reconciliation of the 
chemical gene, the informational gene that 
Francis Crick would recognize, and the 
physiological gene that even Thomas Hunt 
Morgan might recognize. In comparison, 
what kinds of reconciliations were at-
tempted by the Venter Institute’s project? 
Their goal was to produce the minimum 
viable organism as defined by the minimal 
genome, the minimal set of cellular parts 
and pathways and the minimal physiologi-
cal capacities required to keep a cell vi-
able. These three descriptions and mech-
anisms—genome, parts and pathways, 
and physiological capacities—needed to 
be defined exactly and reconciled in their 
project. The second half of the discussion 
will attempt to delineate the accomplish-
ments and limitations of their attempt.
There are at least three aspects of total 
synthesis work. The first is articulating 
established explanations and manipulation 
techniques from decomposition studies 
i. e. pulling things apart and saying ‘this 
thing caused that’. In this aspect, you are 
putting the pinch points between your 
manipulations and explanations to say 
‘we have mechanisms here that we can 
work with and recapitulate what nature 
does.’ Second, you need to show that once 
your identified parts are recomposed, they 
behave as expected. Third, when the target 
phenomenon has multiple dimensions you 
have to reconcile different explanations, 
and the associated manipulations and 
mechanisms, in order to show your 
perspective is complete. In the case of 
Khorana and the gene, the informational, 
chemical and physiological dimensions 
of the gene were reconciled in the total 
synthesis project.
The Khorana Lab combined tools from 
chemistry and biochemistry. The direct 
chemical synthesis was done to obtain the 
small oligonucleotides, but enzyme-based 
12
biochemical reactions were used in the 
construction of the longer length DNA of 
the gene. And also the complementarity of 
duplex DNA was used to bind pieces with 
each other in the correct order to construct 
the whole length gene. Khorana called their 
method the chemical-enzymatic method 
for synthesizing the gene. Through several 
stages, the whole gene is assembled—and 
in their diagram, they depicted each loca-
tion where enzymatic activity is complet-
ing the synthesis with a bump. To demon-
strate the expected behavior of the gene 
they inserted the synthesized gene into a 
disabled version of its home organism—a 
bacteriophage (bacterial virus) lacking a 
copy of this essential gene. This disabled 
version of the bacteriophage is unable to 
complete the final stage of its life cycle in 
bacteria—to break out of the cells—which 
is visualized through the formation of 
plaques on a lawn of bacteria. The syn-
thetic gene successfully restored plaque 
formation behaviour and reversed the dis-
ability of the bacteriophage.
The execution of a Total Synthesis 
project of a target phenomenon also marks 
a historical transition in development and 
integration of the multiple disciplines de-
veloping explanations and manipulations 
of that target phenomenon. This historical 
arc shows the passage from a phase of de-
composition work into a phase of re-com-
position work through a transitional phase 
of reconciliation work. The decomposition 
phase accumulates discoveries of parts 
and their inter-relationships into a stack 
of possible explanations and manipula-
tions. During the reconciliation phase, this 
stack of explanations and manipulations 
are rationalized with respect to the assem-
bly of the whole and its behaviour. As the 
elements of this stack begin to fit together 
some of the explanations are found to be 
lacking and are replaced and some of the 
missing manipulation capacities are speci-
fied and discovered. As the elements of the 
stack begin to fit with each other the total 
stack reduces. The successful execution of 
the Total Synthesis Project marks a recon-
ciled and complete repertoire of explana-
tions and manipulations.  The first total 
synthesis of a gene and the demonstration 
of its biological behaviour reconciled the 
Fig. 3. Visualisation of a historical arc showing passage through stages of decomposition, manipulation 
and re-composition. Copyright retained by Alok Srivastava and Elihu M. Gerson.
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chemical, informational, and physiologi-
cal explanations and manipulations of 
the gene. This full package of repertoires 
of manipulations underlying such a dem-
onstration is portable and transportable. 
In this aspect, the successful execution of 
a total synthesis project of a whole marks 
the passage through a bottleneck in tech-
nology development. The tour-de-force 
efforts offer to all the workers in related 
disciplines a complete circuit of explana-
tions and manipulations for the making 
and remaking of genes at the chemical 
level and the behavior of genes at the bio-
logical level. 
Historically, the first successful total 
synthesis of a gene depended on an array 
of earlier completed work produced by a 
range of different disciplines. We might 
list the central dogma of molecular biol-
ogy, gene structure, physiological activi-
ties of the cell, and chemical-enzymatic 
characterizations of the cell’s proteins as 
capacities available to this project. Impor-
tantly also, the chemical-enzymatic expla-
nations and manipulations of processes 
such as DNA polymerization and RNA 
polymerization had already been worked 
out in in-vitro & cell-free experiments be-
fore this project. These repertoires offered 
the starting stack of explanations and ma-
nipulation at the start of the reconciliation 
work involved this total synthesis project.
Reconciliation work during re-compo-
sition and re-assembly projects empha-
size the role of unique classes of capacities 
called scaffolds and brackets. These are co-
ordination devices to enable work within 
and across multiple levels of the phenom-
enon. This coordination includes the social 
level of the lab personnel and interacting 
disciplines and the physical level on the 
lab workbench and the test-tube. Scaffolds 
are required while a configuration of tar-
get phenomena is being assembled. Suit-
able scaffolds that hold the configuration 
together during and through the interme-
diate stages of assembly. The capacities of 
the scaffold are not built out of the mecha-
nisms inherent in the phenomena but are 
recruited from outside such as the labora-
tory environment. In the Khorana case, a 
range of ways to hold the sequence of the 
gene together was utilized, such as the 
written sequence of the gene, the maps, 
and protocols used to represent the ar-
rangements of the intermediate parts and 
to guide the sequence of assembly.
Brackets, on the other hand, are used 
to hold capacities together when they are 
needed in the same space or time. Some ca-
pacities of the elements of a whole interact 
and need to be kept in place but blocked 
from interacting during assembly and 
some capacities that are not linked need to 
be kept together so that their joint action 
can drive the assembly. These situations 
are articulated with brackets. An example 
is the role of blocking chemistry in these 
experiments to deal with the many active 
centers in a chemical part of a polymeriza-
tion reaction. Blocking agents being added 
to selective sites of a molecular part in 
one reaction to selectively enable a spe-
cific reaction and sequentially removed in 
subsequent reaction steps to enable other 
specific reactions are examples of brack-
ets employed during bench-work. This 
class of coordination devices articulating 
DNA Synthesis in the laboratory has been 
a critical technology in the growth of DNA 
synthesis and it was crucial in the develop-
ment of the capacities packaged in auto-
mated-mechano-chemical DNA synthesis.
Now turning to the Venter study. Their 
claim was that they had designed and syn-
thesised a minimal genome. The intended 
goal of their project was to design and 
demonstrated a minimal and completely 
defined cellular organism. They aimed to 
achieve and demonstrate a reconciliation 
of three intersecting models and mecha-
nisms of the minimal viable genome: the 
minimal set and network of genes, the 
minimal set of cellular parts and pathways 
In the Khorana case, a range of ways to 
hold the sequence of the gene together 
was utilized, such as the written sequence 
of the gene, the maps, and protocols 
used to represent the arrangements of 
the intermediate parts and to guide the 
sequence of assembly.
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and the minimal physiological capacities 
of the cell.
An early accomplishment of the Ven-
ter Institute was to achieve the capacity 
to build genome length molecules of DNA 
from small pieces in surrogate chemical 
and biological environments. They also 
accomplished the ability to replace the na-
tive genome molecule of a host organism 
with the synthesized genome and re-boot 
the physiological life of the host cell with 
the transplanted genome. To achieve this 
the Venter laboratory behaves like a surro-
gate cell and is organized to take on several 
steps carried out by the cell. Several parts 
and sub-assemblies having to be specified, 
organized and held correctly along the 
step-wise process of making and piecing 
them together. The lab here is made up of a 
system of scaffolds and brackets that let it 
substitute for cellular processes. The Ven-
ter Lab acting in this manner as a surro-
gate cell is able to routinely specify, make 
and assemble a full bacterial genome, 
transplant into the host cell and reboot its 
physiological activity, all in three weeks.
However, in their pursuit of minimiz-
ing the list of parts and capacities to sup-
port a minimal organism the Venter group 
hit significant failures. The implemented 
genomes based on previous work from 
top labs such as the George Church group 
defining the minimum list of genes and 
pathways to support a cell. This minimum 
gene set included 166 genes and the trans-
planted organism did not reboot and could 
not be enlivened. Fresh attempts through 
bioinformatics efforts by two separate 
groups at the Venter Institute built alter-
native lists of genes. But the designed ge-
nomes from these two efforts again proved 
unviable and could not be resuscitated by 
additional strategies. At this point they 
went back to traditional genetics, and used 
transposon-mediated deletion analysis of 
each gene, to discover the set of essential 
genes required for viability. Through this 
process, they obtained a reduced gene set. 
But when they built this, it did not live.
At this stage they put back genes that 
they had left out, one by one, to test each 
additional gene for contribution to viabil-
ity. This was a purely empirical effort. It 
was not a design process, this is trial and 
error, trying multiple hundreds. By this 
process, they arrived at one genome that 
was viable. This accidentally successful 
genome had 473 genes compared to the 
original 525 genes. Moreover, one-third of 
the 473 genes are without assigned biologi-
cal functions in the available knowledge of 
microbial molecular biology.
The Venter Institute study misses the 
standards of a total synthesis project as 
practiced by scientists in significant ways. 
The parts and their relations remain un-
known for at least 1/3rd of the genes in 
the viable genome. So if we compare the 
Venter institute’s study to Khorana lab’s 
achievement, we can see that the Venter 
study could not achieve reconciliation of 
the multiple perspectives. Firstly they lack 
a complete list of defined parts on each of 
the three perspectives: the minimal set and 
network of genes, the minimal set of cel-
lular parts and pathways and the minimal 
physiological capacities of the cell. As a re-
sult, their project failed to get going on the 
reconciliation work typical of a total syn-
thesis project. In sum, the contrast in the 
accomplishments of these two projects un-
derscores that making a working system 
from scratch constitutes a distinctive kind 
of knowing, and making cannot substitute 
for explanations.   
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Jane Calvert 
Synthetic yeast: a tale of sixteen synthetic chromosomes
The aim of the synthetic yeast project is to 
redesign the genome of the yeast species 
Saccharomyces cerevisiae. The project is of-
ten referred to as Sc2.0. Several of the chro-
mosomes have already been synthesised, 
and these results were published earlier in 
2017 in Science, so some of you may already 
be familiar with it. There are two main rea-
sons why it is relevant to our discussion to-
day. First, it is the kind of project that peo-
ple only take on thanks to the capacities for 
DNA synthesis. It reflects the kind of sen-
timent I heard expressed by the synthetic 
biologist Christ Voigt at the Synthetic Biol-
ogy 7.0 conference: “Now that we have the 
ability to synthesise anything, what we do 
we build and what do we design with that 
capacity?” I am not necessarily endorsing 
his view that we can synthesize anything, 
but I am highlighting the kind of sense of 
possibility that DNA synthesis often in-
spires. The second reason I wanted to dis-
cuss this project is because of one of the 
questions which this workshop was organ-
ised around, one that resonated with me: 
‘what are the relations between organisms 
in receipt of synthesised DNA and those 
inheriting it from biological production or 
receiving it from another organism?’
The synthetic yeast project places itself 
in a trajectory with previous whole ge-
nome synthesis projects. These normally 
start with the polio virus in 2002. Peo-
ple usually then tell a story which goes 
through the J. Craig Venter Institute’s work 
we heard about in the first talk. So in 2008 
there was the Mycoplasma genitalium ge-
nome, which is one of the smallest known 
bacterial genomes, then there was the 2010 
Mycoplasma mycoides work that Alok spoke 
about. Up to this stage the genomes had 
maybe included a few ‘watermarks’ but 
basically the genome sequences were the 
same as the wild type. With the 2016 paper 
we were introduced to a reduced genome, 
which was very different from the original 
sequence, so we began to see people us-
ing synthesis to change existing genome 
sequences. That same year there was also 
an attempt to systematically recode many 
of the codons in E. coli. The synthetic yeast 
project is an order of magnitude larger 
than previous bacterial genome projects. It 
also aspires to change the genome in many 
ways.
In passing I should mention that some 
people see this as on a path towards the 
synthesis of the human genome, which I 
won’t discuss myself, but Rob Smith will 
address this at the end of the day.
While this overview is the kind of his-
tory people usually recapitulate for the 
synthetic yeast project, others do go back 
further. One of the people on the project 
traces a history of synthesis back to the 
first synthetic gene in 1979, and then from 
there the first synthetic plasmid in 1990, al-
lowing for a broader and bigger trajectory 
of the history of synthesis. By bringing this 
into my talk I want to point out that there 
are many different ways to think about the 
trajectories of synthetic genome projects, 
and that at least some members of the syn-
thetic yeast project want to see themselves 
as part of a longer history than just syn-
thetic biology narrowly understood.
Because yeast is the largest genome to 
be synthesized so far, it has been organised 
as a large international project with many 
different countries involved. The chromo-
somes are distributed around these differ-
ent locations as we see here. The empirical 
work that I will draw on throughout my 
talk has involved spending time visiting 
these labs, attending their conferences, 
and interviewing the practitioners. I will 
discuss three things today. I will start with 
the synthetic yeast project as a whole, be-
fore moving on to specific discussion of 
the synthesis of some of the chromosomes 
When the scientists first set out with the 
goal to design a new yeast, they could 
not easily decide what to do, because the 
number of possibilities was so large. What 
they decided to do was to design a yeast 
that could teach them biology.
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which have distinctive characteristics, and 
then finally arriving at the question of 
species identity and how this project may 
challenge it.
As a whole, the synthetic yeast project is 
often described as a ‘refactoring’ project, 
which is a term that comes from computer 
software engineering, meaning to ration-
alise and clean up software code. Synthetic 
biologists say they are doing the same to 
the genetic code. One of the earliest exam-
ples was the refactoring of bacteriophage 
from 2005. Refactoring is interestingly dif-
ferent from recombination, because it re-
quires an overview of all the changes you 
want to make, it is not just about putting 
different bits of DNA into a recipient cell.
In addition to being a refactoring pro-
ject, the synthetic yeast project is a design 
project. When the scientists first set out 
with the goal to design a new yeast, they 
could not easily decide what to do, because 
the number of possibilities was so large. 
What they decided to do was to design a 
yeast that could teach them biology.
They did this by adopting three design 
principles: (1) maintain the fitness of the 
yeast, (2) maintain genomic stability, (3) in-
crease genetic flexibility. To achieve these 
aims they are making a range of changes to 
the genome, such as removing the introns, 
shortening the telomeres, and reducing 
the number of codons. The final synthetic 
yeast will be 8% shorter than the wild type. 
One of the most interesting design fea-
tures, with the aim of increasing the flex-
ibility of the yeast genome, is the so called 
‘SCRaMbLE’ system. This enables large-
scale genome rearrangements, including 
deletions, inversions, and duplications. It 
provides a new kind of experimental space 
for exploration, and also potentially leads 
to new yeast variants with industrial sig-
nificance. This scramble system has been 
introduced across the whole genome.
The building process started out around 
2007, when they began to order the DNA 
sequences that they needed from com-
mercial companies. But they found this 
was taking too long and was prohibitively 
Fig. 4. Timeline of the production of synthetic genes and genomes, originally published in Sackler Forum 
2015 Trends in synthetic biology and gain of function and regulatory implications. Reprinted with permission 
of Patrick Cai.
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expensive. So they decided to adopt a strat-
egy of relying on undergraduate labour, 
introducing a course called ‘Build a Ge-
nome’ at Johns Hopkins University. The 
undergraduates were supplied with oli-
gonucleotides produced by a synthesiser, 
which they then combined into ‘building 
blocks’. The process has been a stepwise 
one of increasing scale, from so-called 
mini-chunks, to chunks, to mega-chunks. 
Mega-chunks are integrated into the yeast 
genome through homologous recombina-
tion, which is something that the yeast 
do naturally. It’s a stepwise process where 
the synthesised DNA replaces the natural 
DNA sequentially.
The aim, as one of the scientists put it, 
was to ‘create a living yeast cell whose DNA 
traces back to an oligo synthesiser, and be-
fore that to a computer programme rather 
than a parent cell’. This is very reminiscent 
of the Venter Institute’s statements they 
released in 2010 stating that their syn-
thetic Mycoplasma ‘was the first cell to have 
a computer for a parent’. These examples 
matter for our discussion, because they 
show how evolutionary and genealogical 
relationships are cut, raising questions 
about provenance.
Having discussed the project as a whole, 
I will now discuss a couple of the individ-
ual chromosomes in more detail. I’ll start 
with chromosome III, which was the first 
to be synthesised by Johns Hopkins and 
NYU in 2014. It was also the first yeast 
chromosome to be sequenced, in 1992. This 
draws attention to the fact that there are 
perhaps things we need to discuss about 
the parallel histories of sequencing and 
synthesis. Chromosome III is sometimes 
referred to as the ‘sentimental favourite’ 
of yeast geneticists, because it contains the 
genes responsible for sexual behaviour. It 
is also one of the shortest chromosomes, 
which was another reason for choosing to 
synthesise it first. Because it was the first 
chromosome to be synthesized, when they 
came to publish their work, the authors de-
scribed the synthesis of the chromosome. 
This situation put pressure on authors of 
the future chromosome papers, who had to 
think of additional contexts and stories in 
which to situate their work.
The next chromosome I will discuss is 
the ‘neo-chromosome’. The reason for con-
structing this chromosome is to increase 
the stability of the genome overall. The 
scientists have taken the tRNAs, which 
are considered the most unstable parts of 
the genome, and they have put them all to-
gether in one chromosome. The downside 
is of course that you therefore have all the 
unstable elements in one place.
Because of this new chromosome, 
it might look as though the overall 
synthetic yeast will to have an additional 
chromosome. But this is not the case, 
because they are going to combine 
chromosome I and II. This will be done 
partially to keep the same number of 
chromosomes, and partially to increase the 
stability of the refactored and shortened 
chromosomes. At NYU they ran an 
experiment to see how many chromosomes 
could be combined, and found they could 
reduce the number of chromosomes 
substantially. This is a finding that might 
prompt questions regarding the identity 
of organisms and chromosome number, 
because chromosome number is one of 
the ways in which we commonly identify 
organisms.
In respect to species identity, I now want 
to talk about chromosome 12, which was 
synthesised at Tsinghua University. An 
important point here is that China is a very 
important country for the synthetic yeast 
project, with Tianjin University and BGI 
also involved. An interesting feature of 
chromosome 12 is that it has the ‘barcode’ 
for species identity. This barcode is used 
to identify Saccharomyces cerevisiae, which 
is a redundant and repetitive region in the 
wild type which we use in order to iden-
tify the species. But because it is redun-
dant and repetitive the synthetic genome 
project has deleted it. Does this mean that 
the synthetic yeast is no longer the same 
species? This was a question that the sci-
entists themselves raised. I see it as related 
to broader questions of species identity.
There are perhaps things we need to dis-
cuss about the parallel histories of se-
quencing and synthesis
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Lastly I will explain three of the chromo-
somes that have come late to the project, 
which are not particularly distinctive, but 
they raise questions for large genome syn-
thesis projects. Macquarie University in 
Australia has two large chromosomes, and 
when I asked what was special or interest-
ing about their chromosomes they did not 
identify any particular features. But what 
is interesting about their work is that they 
have a collaboration with the Australian 
Wine Research Institute. With AWRI they 
are building a ‘pan-genome neo-chromo-
some’. They are taking the genes that are 
found in industrial strains, for instance the 
ones that are found in wine-making yeast, 
and putting them into a separate chromo-
some. This is not strictly part of the syn-
thetic yeast project, but is something that 
they decided to do. This points to the kind 
of experimental space that is opened up by 
the project itself, and indeed a few of the 
other labs have also decided to create their 
own neo-chromosomes.
The final chromosome I will discuss is 
being synthesised by the National Univer-
sity of Singapore, the last group to join the 
project. This is chromosome XV, which is 
a very large chromosome. Here I want to 
draw attention to the fact that size mat-
ters and that building large chromosomes 
can be a laborious and mundane task. This 
contrasts with rhetoric in synthetic biol-
ogy that sees design and construction be-
coming two separate spheres, with design 
requiring all the creativity, and construc-
tion being the boring bit, being taken over 
by machines in the future, or so it is hoped.
Group discussion
Marv. Has the neo-chromosome been syn-
thesised already, and has it been made sta-
ble?
Jane. Yes they made it stable, it was a lot 
of work, not yet published. Required lots 
of knowledge of tRNAs, had to get flank-
ing regions from different yeast species, 
it actually has 9 different species involved 
in the neo-chromosome in order to make 
it orthogonal to the rest of the system. 
They also are building it to have a different 
SCRaMbLE mechanism built in. 
Marv. But when you put it into the total 
genome, with all the tRNAs are on that one 
chromosome, somehow one of those con-
structs has to figure out how to be stable in 
order for the cell to survive. But you won’t 
know which one that is, just one of those 
neo-chromosomes will have to be stable.
Jane. There is an interesting project 
looking at the chromosome structure in 
3D and how they fold. The image of the 
neo-chromosome in comparison to the 
other ones, it just looks like a tiny curled 
up thing. I do not know what that implies 
about how it will coexist with the others. 
Marv. That leads me to ask, the one that 
works, i.e. that gets inside the cell, does 
it still have the same sequence as the one 
they made, or has it been recombined in a 
way that is surviving?
Jane. They do sequence it regularly to 
try and check, but I am not sure how long it 
takes for mutations or changes to happen. 
The publication of the papers in Science, in 
one of them they were keen to point out 
that it was a perfect copy of the design and 
came out exactly as it was meant to, but I 
do not know how long it stays like that.
Lijing. It seems that the two projects, 
Khorana and the synthetic yeast, are two 
modes of synthetic biology happening 
at different times, and are reflective of 
two different views at these times of how 
biology works. One way to synthesise a 
gene is to figure out each piece of the en-
zymatic process necessary, and through 
trial and error, asking new questions that 
build postdocs and people’s careers over 
time. But in recent years we see a move to 
a more global conglomerate and large in-
ternational collaborative approach, both to 
sequencing and synthetic biology. We also 
see this shift in ‘big data’ biology. How do 
the speakers see their cases fit into a larger 
historical context?
Jane. I agree that the parallel of 
sequencing and synthesis is very 
important. I think it also matters that some 
of the people involved in the synthetic 
yeast project like to connect themselves to 
the longer history of gene synthesis, where 
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other synthetic biologists might focus on 
a turn of the millenium context, and a 
renewed emphasis on the importance of 
engineering for biology. Venter has been 
doing the mycoplasma work for a very long 
time indeed. 
Alok. The cell is very complicated. The 
number of tasks that it does is large. The 
fact that 17 chromosomes are being at-
tempted across the globe, people are learn-
ing what it takes, and organising their 
project to find what it takes. I think the 
scale of project is matching the scale of the 
task structure. Also if we compare the two, 
the Venter project is working on some-
thing 1/6th the scale of the yeast genome. 
Marv. This is not a synthesis story, 
but Spiegelman in the late 60s, I think it 
was bacteriophage R17, he put it under 
the pressure of time. He asked ‘if I keep 
shortening the amount of time, what will 
happen?’ And the answer is he was able 
to reduce the time it took to replicate that 
genome in the test tube from, I don’t know 
what the numbers are, let’s say an hour to 
five minutes. This organism learnt how to 
do it by shortening the chromosome and 
only putting the essential parts in, and the 
rest was discarded. Now in those days they 
could not sequence it properly so they had 
no idea what the sequence was.
Jane. Time is very interesting also in the 
Venter Institute’s work, because they de-
cided to move from the  Mycoplasma geni-
talium to the Mycoplasma mycoides because 
the former was very slow growing. 
Alok. Indeed the genitalium was slow 
growing to the extent that it did not have a 
defined doubling time. There is also a ques-
tion of how much of the physiology we are 
able to map and play with. We do not un-
derstand the physiology that produces the 
doubling time, so this is not engineering 
in the hands of Venter because they do not 
know how doubling works. What is nice 
about the Spiegelman example is that you 
do not claim to know how doubling time 
shifts from an hour to five minutes. But if 
you let the cell replicate under pressure it 
will shuffle the mechanisms and make it 
happen, and you can come along and read 
out the sequence. But you are not design-
ing or claiming to explicate. 
Marv. Well I see design and synthesis 
going hand in hand. You go from synthe-
sis to design, from synthesis to design, 
and you get to the end product of your 
process. 
Roger. This to me is also how technology 
works. People try things and then see what 
works, change it, and see what works.
Jane. Synthetic biologists do talk about 
wanting control. They want to be able to 
design it and for it to work as intended. 
 Marv. Another question I had was to do 
with the labour involved. And the reliance 
on undergraduate labour. Well in indus-
trial synthesis, even with the best chemis-
tries, there is roughly 1 mutation every 500 
nucleotides. So you have to put them to-
gether in blocks, then clone and sequence 
them in order to find the one that is right. 
That’s where the labour comes in. Now, if 
you could improve the chemistry to bring 
this up to 1 mutation in every 2000 nucle-
otides, you might be able to get away with 
a lot less labour. 
Dominic. I felt that in both papers there 
were always tensions about what to val-
ue at a given time. So in the first paper it 
was explained how so much of this was a 
chemical enterprise, but then to synthe-
sis the gene they really had to rely on the 
biology. Could you both say more about 
these tensions? The times when labour is 
labour, and not that great, and times when 
labour is engineering and something more 
impressive. Or the times when a particular 
phenomena is worthy of attention or not 
worthy, because by alluding to it you might 
just actually expose your ignorance. Or the 
times when having an explanation seems 
to matter, and when it doesn’t.
Jane. One of the heads of the synthetic 
yeast project is famous for some work on 
transposons, but in this genome they are 
getting rid of them. So in their case they 
once valued these components of a chro-
mosome, but are now deleting them, which 
I think is a good example of something’s 
value changing. 
Marv. Do they know if they can delete 
all those transposons?
Jane. A lot of the deletions go wrong, 
and they find they have to put them back in 
again. Likewise with introns.
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Marv. I would imagine that you’re going 
to get a lot of people groaning very loudly 
when they realise that in order to use the 
synthetic yeast to explore a particular 
function, you’re going to have to resynthe-
sise x-number of chromosomes to recover 
the function you want to look at. Or the 
groans will come when they try and make 
the whole thing actually survive. 
Alok.  The question brought attention 
to differences between chemists and biolo-
gists, and the chemist recruiting the biol-
ogy’s unknown ability to complete the syn-
thesis. The other tension here is between 
explaining and manipulating, and putting 
a technology in a box. Manipulation is a lot 
of fun, it gives you an enormous amount of 
novelty, but then there is bookkeeping to 
do for explanation.
 Jeff. Something has changed to simplify 
these procedures to the degree that under-
graduates or high school students can con-
tribute to these international efforts.
Marv. High school students these 
days will usually be highly skilled when 
it comes to ligating and cloning. Having 
huge amounts of labour to achieve 
something in biology is not new. The first 
tRNA that was chemically synthesised 
with all the modified bases, that was done 
in China around 1978–81/2. They had 
literally a factory outside of Shanghai 
that did nothing but take natural tRNAs 
and fractionate them and isolate all the 
modified bases that went into a tRNA. A 
massive effort, 500, 1000 people? I don’t 
know. Once they had enough of this 
material to put into a synthetic gene, they 
shipped it to the Shanghai Institute of 
Biochemistry and they then incorporated 
these modified bases into the right sites. 
So this was lots of labour too, it wasn’t high 
school students but it was workers in a 
factory.
Jeff. So the ability to mechanise the 
process matters. But doesn’t this require 
fundamental advances? If we look at Emil 
Fischer trying to synthesise proteins, he 
could never do it because he hasn’t figured 
out the correct technique, so it wouldn’t 
matter how many people he put on the job, 
he’s not going to get there. 
Session 2: Extending synthesis
L. Scott Cole 
Selling DNA Synthesis: Applied Biosystems’ DNA Synthesis Business 
from 1989–1992
This morning I’ll be discussing the dissem-
ination of automated DNA synthesis tech-
nology. That’s what we did at a company 
called Applied Biosystems, or ABI, where 
I worked in the DNA synthesis group from 
about 1989 to 1992. Briefly, my background 
is in molecular biology. That’s what I stud-
ied as an undergrad and in grad school, 
then I went to business school with the 
idea of working in the biotech industry. 
My first job was as product manager for 
the DNA synthesis business at ABI. I start-
ed there after the company had launched 
its first DNA synthesizer in 1983. So, for 
the earlier part of the brief history I’ll be 
presenting today, I’ll be relying on inter-
views I conducted recently with other ABI 
employees involved in DNA synthesis be-
fore me.
My presentation has three sections. 
First, I’ll be talking about DNA synthesis 
platforms and technology. Second, I’ll take 
an inward-looking view of the company, 
i.e. the people, processes and culture at 
ABI. Lastly, I’ll take an outward view, i.e. 
focused on ABI’s customers, applications, 
and competitors. I will present each with 
respect to two time periods: (1) 1983–87, 
which I call “market entry and develop-
ment”, and (2) 1988–1992, which I call 
“rapid market growth.” The turning point 
corresponds with the commercial intro-
duction of PCR technology, which drove 
growth in DNA synthesis. The reverse is 
also true: automated DNA synthesis ena-
bled PCR technology to flourish.
What is a DNA synthesiser? Curt Becker, 
one of ABI’s first employees called it a ‘glori-
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fied Coke machine’ since it’s fundamentally 
a liquid delivery system. A DNA synthesiz-
er builds DNA strands (“oligonucleotides” 
or just “oligos”) in disposable cartridges 
called “columns.” A column contains a 
solid support matrix—basically, very small 
glass beads—upon which the oligos are 
synthesized base by base. The instrument 
performs successive cycles of chemistry. 
Every cycle adds a new base to the growing 
chain. At the end, the instrument performs 
a round of chemistry to cleave the synthe-
sized oligos off the glass beads so they can 
be used in an experiment.
Automating DNA synthesis involved at 
least two challenges. First, the chemical 
bases in their precursor form, “phospho-
ramidites”, are very expensive. This puts a 
premium on using very small amounts of 
chemicals in each synthesis cycle. Second, 
a few of the non-phosphoramidite rea-
gents used in the synthesis cycle are toxic. 
A DNA synthesizer is designed to sit on a 
lab bench and not in an air flow hood, so 
the synthesis process has to be completely 
contained.
From a customer perspective, there are 
at least three important performance met-
rics. First, customers want very low rea-
gent consumption. Again, this is because 
the phosphoramidites are so expensive. 
Second, they care about “coupling efficien-
cy.”  This refers to the chemical efficiency 
of each base addition and determines the 
ultimate amount and quality of the oligo 
and the potential length of an oligo. Con-
sider that if coupling efficiency is even 
90% at each base addition, the 10% loss 
compounds with every base addition cycle 
and it becomes difficult to make even small 
oligos. Finally, customers care about “cycle 
time.” How long does it take to make an 
oligo and therefore how many can I make 
in a day?
Let me provide some context regarding 
ABI. The company was founded in 1981 
thanks to two complementary academic 
efforts: those of Marvin Caruthers’ lab 
at University of Colorado, which focused 
on DNA synthesis chemistry, and of Lee 
Hood’s lab at Caltech, which focused on au-
tomation. In fact, many of ABI’s early em-
ployees came from these two labs, and also 
from Hewlett Packard, which was the larg-
est instrument company in the Bay Area at 
the time. ABI’s first product was a protein 
sequencer. The second was the DNA syn-
thesiser.
Fig. 5. Clockwise from top, (i) Andre Marion 
(left) and Sam Eletr; originally published 
in Springer, Mark (2006). ‘Applied Biosys-
tems: Celebrating 25 years of advancing 
science’, American Laboratory News. (ii) 
Bill Efcavitch (left), Steve Lombardi, and 
Scott Cole (right); photograph courtesy of 
Scott Cole. (iii) Michael Hunkapiller; pho-
tograph courtesy of Scott Cole.
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Let me quickly give you a sense of ABI’s 
early team and culture. The company 
had two founders: Sam Eletr and Andre 
Marion. Sam was a former H-P engineer: 
by all accounts very technically-oriented, 
competitive, demanding and even intimi-
dating. But he was highly respected and 
really set the company’s fairly aggressive, 
demanding culture. André was also an en-
gineer. He worked with Sam at H-P and 
was the quieter of the two. A third key per-
son early on was Mike Hunkapiller. Mike 
was a post-doc in Lee Hood’s lab at Caltech 
and joined the company pretty soon after 
it was founded. Mike would eventually 
become ABI’s president during much of 
the 90s and beyond. The fourth person I’ll 
mention is Bill Efcavitch, a chemist from 
Dr. Caruthers’ lab who was the head R&D 
person in the early years and beyond.
In short, the early team was engineer-
ing-focused and very competitive, with 
some strong personalities. ABI was not a 
“marketing-driven” company. Marketing 
as a corporate function was not highly re-
spected. To be successful in marketing at 
ABI, really throughout the company’s ex-
istence, you had to not only be able to keep 
up with the technical folks, you sometimes 
had to be capable of challenging them on 
technical matters.
ABI’s culture and strong market posi-
tion gave it a reputation in the market as 
being an arrogant company. A 2000 New 
York Times article about ABI said that in 
its customers’ minds, “ABI” stood for “Ar-
rogance Beyond Imagination.” I more re-
cently heard a story—so this is second 
hand—that when the protein sequenc-
er, the company’s first instrument, was 
launched, a salesperson would visit a po-
tential customer lab and if that lab didn’t 
place an order within three hours he or she 
would leave. Again, I can’t vouch for that, 
but it wouldn’t surprise me. Another quote 
from that same New York Times article was 
from the director of a large genome se-
quencing center (who was also a DNA syn-
thesis customer) who said about ABI that, 
‘It’s not that the customer is always right, 
the customer is always wrong’. These 
quotes highlight some negative aspects of 
ABI’s culture, but that culture also made 
the company successful and made ABI an 
exciting, dynamic, passion-filled place to 
work.
Sam and Andre’s early vision was, in 
their words, to sell the picks and shovels 
to the miners in the biotech gold mine. 
The other pitch the founders made to 
early investors was that ABI was going 
to offer everything required for molecu-
lar biological research. That meant that 
for both proteins and DNA, ABI would 
develop platforms for both synthesis and 
sequencing. And it did. It launched these 
platform capabilities in the following or-
der: protein sequencing, DNA synthesis, 
peptide synthesis, and DNA sequencing. 
The commercialization of these four types 
of platform delivered steady, rapid growth. 
As one platform would begin to plateau in 
the market, a new one would pop up and 
take its place, and so on. These successive 
roll-outs culminated with DNA sequenc-
ing, Celera Genomics and the sequencing 
of the human genome, which I probably 
won’t have time to talk about.
But focusing again on DNA synthesis, 
the company launched its first DNA syn-
thesizer, the 380A, in 1983. It was large 
and weighed a ton. It was a workhorse. It 
had three columns, so the user could make 
three oligos simultaneously. In 1983, many 
of the customers of DNA synthesizers were 
organic chemist “tinkerers.” They weren’t 
using the phosphoramidite chemistry that 
would eventually dominate the market, 
but a type of chemistry that was more 
“tinkerable.” Many of these users had their 
own “recipes”—their own unique versions 
of DNA synthesis chemistry—that they 
wanted to implement on the instrument. 
The applications at the time that required 
synthetic oligos included studies of DNA-
protein interactions and also reverse ge-
netics. The latter required both a protein 
sequencer, which was ABI’s first product, 
and a DNA synthesiser. If you could get 
the first bit of the sequence from a protein, 
you could create an oligonucleotide that 
What is a DNA synthesiser? Curt Becker, 
one of ABI’s first employees called it a 
‘glorified Coke machine’
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corresponded from a DNA code standpoint 
to its gene. The researcher could then use 
the oligo to find the gene and clone it. That 
was a way to use both of these instruments 
to do something that at the time was very 
novel and important.
Competition during this earlier period 
came mainly from Beckman, Biosearch, 
and Advanced ChemTech. Beckman had 
a tight relationship with Caltech. So it 
wasn’t easy to establish a relationship with 
Caltech and get the licenses required to 
commercialize DNA synthesis technology. 
Most of ABI’s intellectual property licenses 
were also made available to Beckman early 
on. [From the audience: Arnold Beckman 
was on the Caltech board]. That’s right, 
and there’s a Beckman building and Beck-
man everything down there. At the time, 
Sam Eletr made the argument to Caltech 
that large companies like Beckman with 
a lot of products wouldn’t put that much 
effort into selling or developing Caltech’s 
machines, whereas ABI was small and 
hungry and would focus on it much more. 
And probably that ended up being true.
When the 380A launched, the compet-
ing instruments were smaller and less ex-
pensive than the 380A, and in some ways 
were more flexible. By comparison the 
380A was like a Mercedes: big, solid, heavy 
and expensive. One aspect of the 380A and 
other ABI instruments that we always em-
phasized was their “valve blocks.” These 
valve blocks replaced the flexible tubes 
that transported liquids on competing in-
struments. They were developed at Caltech 
and were unique to our instruments. They 
resulted in very low liquid volume waste, 
less mixing, and better cleaning between 
cycles. We would always claim that we had 
the most precise, frugal liquid handling 
technology on the market.
But, again, those other instruments 
were much less expensive, and some labs 
just didn’t have the money for a 380A or, 
later, the very similar 380B. So, in 1985 ABI 
launched a smaller synthesizer called the 
381. It had one column and was much less 
expensive. The idea was to stop Pharmacia 
in the places they were strong, namely Eu-
rope and Japan, and to fight the company 
that by then was called Milligen Biosearch 
in the US. Their Cyclone was really a pretty 
good DNA synthesizer.  
Then, in 1985 the market changed with 
the introduction of a technique called PCR, 
which is essentially a way to make very 
large quantities of any relatively small 
stretch DNA. Think of a photocopier. PCR 
was important to our business because any 
time a researcher wanted to do PCR they 
needed to make two small oligos of unique 
sequence. So, labs were now constantly 
needing small oligos. PCR was invented 
in 1983, presented at a conference in 1985, 
in 1987 it was starting to become commer-
cially available. Then it absolutely took 
off and this was a game changer for DNA 
synthesis. Again, the relationship between 
PCR and DNA synthesis was synergistic. 
PCR drove DNA synthesis sales. But DNA 
synthesis was required for PCR technology 
to spread as fast as it did.
To take advantage of the PCR oppor-
tunity, in 1989 we launched the 391 PCR-
MATE. This was basically a 381 that was 
rebranded, updated with a more modern 
user interface, and cost-reduced a bit. We 
also sold it as “user-installable” for about 
$3,000 less than the same instrument in-
stalled by an ABI service technician. We 
did this to better compete with our lower 
priced competitors. Really, though, the 391 
was never installed by a user because no 
salesperson wanted to risk having a cus-
tomer mess up the install. So, the 391 was 
pretty reasonably priced if you bought it as 
user-installable and then took advantage 
of your salesperson’s offer to help!
The 391 helped us ride the PCR wave. 
Then, in 1991, we launched what became 
the very popular 392 and 394 instruments. 
These were basically one and the same in-
strument outfitted with either 2 or 4 col-
In 1983, many of the customers of 
DNA synthesizers were organic chem-
ist “tinkerers.” They weren’t using 
the phosphoramidite chemistry that 
would eventually dominate the mar-
ket, but a type of chemistry that was 
more “tinkerable.”
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umns, and either 5 or 8 phosphoramidite 
positions. And everything was upgradable 
after purchase. In other words, if the cus-
tomer only had enough money for a 392, 
they knew that when they got more grant 
money they could upgrade their instru-
ment to 4 columns. And, just as important, 
both the 392 and 394 finally had columns 
in multiples of two, which makes sense 
for PCR since a PCR amplification always 
requires two oligos. This was constantly a 
sales issues with the 391 versus its mostly 
2-column competitors: “You call it the ‘PCR 
MATE’ but it only has one column!”
By the late 1980s, oligos for PCR repre-
sented about 90% of the demand. And by 
this time typical DNA synthesizer cus-
tomers were no longer organic chemist 
tinkerers. Customers were now molecular 
biologists. ABI had become far and away 
the market leader because of their instru-
ments’ performance and reliability but 
they were expensive for an individual lab. 
So, departments started setting up what 
became known as “core labs.” These were 
centralized facilities managed by a small 
staff. They enabled shared purchase and 
shared use of expensive instrumentation 
among several or many labs in a depart-
ment.
In the early 90s, competition was still 
coming from some of the same companies 
I mentioned earlier. But now there were 
also competitors that only offered DNA 
synthesis reagents. Companies wanted to 
take away our reagents business, and some 
of the companies were offering high qual-
ity reagents. ABI always had a policy that 
if customers used non-ABI reagents, they 
would void their instrument warranty. 
Customers didn’t like this. It was the epito-
me of ‘Arrogance Beyond Imagination’. But 
it helped us maintain most of our reagent 
business. Our other selling point around 
that time was our “whole product” ap-
proach. ABI emphasized that in addition to 
instrument and reagents, a DNA synthesis 
supplier had to provide strong service and 
support. Given our market dominance, we 
had the largest and best service and sup-
port organization by a long shot. Customer 
conservatism also helped us. Customers 
felt safe going with the market leader. 
There’s an old saying: “Nobody ever got 
fired for buying an IBM mainframe com-
puter.” The same was said about ABI.
Now for a quick internal perspective. 
During the time I’ve been talking about, 
processes within the company remained 
pretty flexible. If a product manager had to 
get around things or do something quickly, 
he or she could. And the technical knowl-
edge within the company was unrivalled. 
The main Foster City (California) campus 
housed employees who knew an enormous 
amount about the various technologies 
relevant to DNA synthesis and who knew 
how to design, develop and manufacture 
very high quality instruments and rea-
gents. Being near Silicon Valley, ABI had 
access to a lot of experienced engineers 
and scientists. And globally we typically 
Fig. 6. Left, a photograph of a 380B model, launched in 1985. It looks very similar to the 380A; image 
courtesy of Scott Cole. Right, Bill Efcavitch overseeing the installation of the 380A in the Caruthers lab, 
1983; photograph courtesy of Marvin H. Caruthers.
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had more than 80% market share. That 
meant we had the most salespeople talk-
ing to the most customers. Tech companies 
often get the best new product ideas from 
customers. Up to a point, success creates 
more success.
After 1992, commercial oligo services be-
gan to take off. Researchers stopped buy-
ing as many synthesisers and instead or-
dered them through the mail. And, around 
this time, ABI started focussing more on 
DNA sequencing. As I said before, sales 
of a new instrument platform can grow 
very quickly for several or more years, but 
eventually start to plateau. That’s when it’s 
important to launch a new kind of instru-
ment that has greater growth potential. 
So, the objective at this time was mainly to 
protect our DNA synthesiser business. We 
did this by continuing to innovate: offering 
smaller columns for less expensive synthe-
sis on the 392 and 394 and also by releasing 
of a much higher throughput instrument: 
the 3948. There was also growing interest 
in other applications, such as large-scale 
RNA synthesis for pharmaceutical appli-
cations, at least their research divisions.
Time is up, so I’ll conclude by quickly 
emphasizing a few the points I made ear-
lier. First, I want to emphasize the impor-
tance of the culture and community in the 
success of ABI’s DNA synthesis business. 
Second, I hopefully conveyed the degree 
to which commercializing a platform like 
an automated DNA synthesizer requires 
a highly multi-disciplinary scientific and 
engineering team. Finally, history shows 
how various research technologies are 
interlinked, both technically and in the 
market. Recall the synergy between ABI’s 
protein sequencer and DNA synthesizer in 
early reverse genetics applications as well 
as the mutual dependence of DNA synthe-
sis and PCR for each of their proliferation 
and success.
Our other selling point around that time 
was our “whole product” approach. 
ABI emphasized that in addition to 
instrument and reagents, a DNA synthesis 
supplier had to provide strong service and 
support
Marvin H. Caruthers 
The Chemical Synthesis of DNA, RNA, and Certain Analogs
I am intending to give you some more of 
the history of DNA synthesis, to give you 
some stories and go from there. I would 
like to start with a quote from Frederick 
Sanger, where he is discussing his work on 
DNA sequencing. “Most of the significant 
work has been summarized in a number 
of reviews and articles. In these there was, 
of necessity, a good deal of simplification 
and omission of detail, both for reasons 
of space and, sometimes, to make a good 
and logical story. With the passage of time 
even I find myself accepting such simpli-
fied accounts”—I too will be giving you a 
simplified overview of several topics along 
the way, through the history of DNA syn-
thesis.
In 2005 I had the honour at the 50th an-
niversary of the first synthesis of a dinu-
cleotide in Cambridge, of presenting the 
introductory talk, which I gave as a history 
of DNA synthesis. So I have a whole lecture 
of slides on this topic, and I started with 
Lord Todd. It was published in the Journal of 
the Chemical Society. Todd was best known 
because he determined that DNA and RNA 
were made of ribose and deoxyribose sug-
ars, and the linkages were phosphate 3–5, 
sugars were linked to the nucleoside bases, 
and he defined the structures of all these 
components, the bases included. This was 
mainly in the 1940s but some of the work 
in the 1930s, and was the main focus of 
his Nobel prize. When he completed the 
synthesis in 1955, in his Nobel lecture two 
years later, he states “synthesis can serve 
not only in the elucidation of structure, 
but can in many instances open up wider 
vistas regarding the significance and func-
tion of biologically important compounds”. 
In other words, unlike most organic chem-
ists, at least 99% of them, who were using 
synthesis just to attack organic synthesis 
problems, such as a 20 or 30 step proposal 
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to synthesise some natural product, and 
once it was synthesised move onto the next 
one, rather Todd’s focus was building these 
new molecules with a focus on biologically 
important compounds that could be used 
to attack biology. He was saying this as ear-
ly as 1955, long before the concept of bio-
organic chemistry which became popular 
in the 1980s and 90s.
Then Khorana came along. He got his 
PhD with George Kenner in Liverpool, 
moved to do a postdoc in Prelog’s labora-
tory at the ETH in Switzerland, and then 
moved to Cambridge to work in Todd’s 
group, where he developed the method-
ologies for forming pyrophosphates and 
synthesising ATP and coenzyme A. And 
then he moved onto the problem of syn-
thesising oligonucleotides. The first major 
involvement with them was using repeat-
ing trimers, and tetramers, and dimers, 
to help elucidate the genetic code, and for 
that he shared the Nobel prize with Mar-
shall Nirenberg. Later on, I myself got into 
the Khorana lab in the late 1960s, and the 
project that was under way at that time was 
trying to synthesise a gene. At the time we 
started this project in 1965 there was only 
one specific RNA sequence that had been 
carried through and that was Bob Holley’s 
work on yeast tRNA alanine. So Gobind 
set up the lab and started to synthesise the 
gene for this particular transfer RNA, with 
the sequence that came out of Holley’s lab. 
Why did he want to do this?
The following quotation comes from a 
jubilee lecture in 1968, ‘why would anyone 
want to synthesise a gene?’ His objective 
was to develop methods where you could 
precisely define the sequence of DNA that 
you put into a piece of synthetic DNA. He 
says: “We would like to know, for example, 
what the initiation and termination sig-
nals for RNA polymerase are, what kind of 
sequences are recognized by repressors, by 
host modification and host restrictive en-
zymes and by enzymes involved in genetic 
recombination and so on.” He goes on, “ the 
next long-range aim must be the develop-
ment of methods for the total synthesis of 
biologically specific DNA duplexes”. He 
was using the synthesis of this gene as a 
template to develop the technologies to de-
fine sequences of DNA. This was the pur-
pose of this work. 
It is worth commenting how much work 
it took to chemically synthesise a 20mer 
at this time. For instance, one part of the 
duplex for this part of the tRNA gene was 
synthesised by Hans Weber, and it was a 
two year project. It took him two years to 
make that 20mer in the mid to late 1960s.
All the assemblies of the gene were ac-
complished by synthesis plus ligation, ar-
Fig. 7. Har Gobind Khorana in 1970. Associated Press, file 700602089.
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riving at the final product of the 77 piece 
duplex DNA. But the point is that this was 
a template for developing methods for se-
quence defined synthesis of DNA. We felt 
it was quite an achievement successfully 
putting together a 77 base pair duplex. We 
then published the 13 papers correspond-
ing to this total synthesis as one complete 
issue of the Journal of Molecular Biology 
which came out in December of 1970. Sub-
sequently a commentary that came out in 
Nature, from a cell biology correspondent, 
states “the thirteen articles from Horana’s 
group which comprise a complete issue 
of the Journal of Molecular Biology surely 
set something of a record....Every step of 
this synthesis has obviously been execut-
ed with consummate skill and the whole 
constitutes perhaps the greatest tour de 
force organic and biochemists have yet 
achieved.” I think I would agree with that, 
and Gobind’s whole view was on the very 
horizon of what you can do, so everything 
you do there is a tour de force, it is never 
done simply. But then here comes the 
zinger: “Like NASA with its Apollo pro-
gramme, Khorana’s group has shown it can 
be done, and both feats may well never be 
repeated”. Many times when I am present-
ing in England, if I know there is a Nature 
editor in the room, I try and bring this slide 
up.
I also want to add a quote from a paper 
that Khorana gave in 1968: “I wish to con-
clude by hazarding the following rather 
long-range predictions. In the years ahead, 
genes are going to be synthesized. The next 
steps would be to learn to manipulate the 
information content of genes and to learn 
to insert them into and delete them from 
the genetic systems. When, in the distant 
future, all this comes to pass, the tempta-
tion to change our biology will be very 
strong.” That was 1968, at an international 
biochemistry meeting in Japan, he had this 
as part of his talk. Of course we are already 
doing that with yeast and several other or-
ganisms. 
The point here is that we could not ex-
press that tRNA gene biologically. So in 
1968 we started work on the synthesis of 
Tyrosine Suppressor tRNA. The idea this 
time was to synthesise a gene that we could 
express and look at its biological activity. 
Here we looked at lambda phage virulence. 
There is a story here I want to tell you about. 
We sat down in one afternoon in 1969 I 
think, to lay out the synthesis of this struc-
tural gene. We spent 2 or 3 hours doing this 
because Gobind had a history of going to 
La Jolla in January, there was a small group 
that Francis Crick put together where they 
would come and talk about their research 
every year, and Gobind wanted to present 
the plan for synthesising this gene at that 
meeting. After spending a few hours talk-
ing about how to synthesise it, we turned 
to the discussion of how we were going 
to express this gene. Well at that time we 
didn’t know anything about promoters, 
or terminators, how to get this gene into a 
cell, or anything like that. So we sat around 
and talked about it for a while. The only 
clue we had to go on, was that Ray Wu at 
Cornell had just sequenced, by a very diffi-
cult methodology, the sticky ends of phage 
lambda. We kind of thought ‘maybe there 
is some way we can attach this to the sticky 
ends of lambda and try to transfect it, sit 
down on our knees and hope and pray that 
something would come out of that’. We had 
no way of knowing how to incorporate this 
synthetic gene into a bacterium and have 
it be expressed. So Gobind was listening to 
all this, and this is what is important, after 
about 25–30 minutes had gone by he stood 
up - in other words the meeting was over - 
and he said ‘well let’s synthesise the gene 
first, and by the time we get it synthesised 
we will know how to express it’. In other 
words, science is going to move far enough 
along that we will know how to express it, 
and that is the way that Gobind did his sci-
ence. 
Our lab has the honour of being one of the 
first two labs to show that synthetic DNA 
has biological function. Both my lab in 
Boulder and Arthur Riggs in collabora-
tion with Saran Narang, had synthesised 
the lac operator sequence, both by differ-
ent methodologies but we got the same 
sequence
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After Gobind’s death in 2011, myself 
and Robert Wells in our retrospective, we 
wrote: “Gobind was a dedicated, driven, 
focused, and humble scientist. He was 
fiercely loyal to all whom he mentored and 
worked with, and unyielding in his drive 
toward the highest scientific ideals and 
goals. He repeatedly attacked immense 
and challenging problems, likely with lit-
tle idea of how he would eventually solve 
them—but solve them he did.” That was 
Khorana. 
I was fortunate that I worked with Bob 
Letsinger as a graduate student. When I 
spoke to him, as you’re interviewing for 
places to pursue your work, he was try-
ing to develop methods for synthesising 
macromolecules on polymer supports, and 
I thought that was really a neat idea be-
cause nobody had ever tried that before. I 
specifically chose North Western to work 
with Bob, and so as soon as I arrived I be-
gan working in his lab. At that time he had 
a postdoc in his lab, Milt Kornet, who had 
just synthesised a dipeptide on a polysty-
rene support, and we were pretty excited 
about that. A month or so later, Merri-
field published his Tetrapeptide synthesis 
in JACS also on polymer support, and the 
two labs didn’t know that the other was 
working in that area. Bob and Milt wrote 
up their work and published it all the same 
year in JACS as Bruce Merrifield’s work. 
Unfortunately Bob did not share that Nobel 
prize, it was given entirely to Merrifield. 
But Bob turned his attention to DNA syn-
thesis and figured out a new method for 
making DNA, again on a polymer support. 
Myself and a number of other research-
ers in the lab worked on other methods for 
synthesising on a polymer support as well, 
and all this came down in the middle to 
late 1960s. Here I quote from a short article 
I wrote about Bob: “Over the years, as I ob-
served how others direct their programs, I 
consider myself one of the most fortunate 
of graduate students. Somehow, I found a 
mentor who was patient, who allowed stu-
dents to explore their potential, and who 
focused his research on extremely chal-
lenging problems.” That was Bob. 
We went ahead, and our lab has the hon-
our of being one of the first two labs to show 
that synthetic DNA has biological func-
tion. Both my lab in Boulder and Arthur 
Riggs in collaboration with Saran Narang, 
had synthesised the lac operator sequence, 
both by different methodologies but we got 
Fig. 8. Slide depicting the process of synthesising DNA through the solid phase approach. Image cour-
tesy of Marvin H. Caruthers. 
29
the same sequence. And then in collabora-
tion with Jack Sadler down in the medical 
school in Colorado, and Saran in collabo-
ration with Art Riggs at City of Hope, we 
independently cloned this operator into E. 
coli and got expression. This was presented 
at the Cold Spring Harbour Symposium in 
1976. Their group published in Nature, and 
we held off until 1977 to publish in the first 
issue of the new journal Gene. This was the 
first piece of synthetic DNA that showed 
biological activity that had ever been pub-
lished. From there using the chemistries 
that Bob Letsinger pioneered various labs 
started synthesising biologically interest-
ing DNAs. Shortly thereafter, Genentech 
in collaboration with Art Riggs at City of 
Hope, published the synthesis and clon-
ing of human insulin, so both the synthe-
sis and the biological activity. By that time 
two graduate students from my lab had 
gone on to become two of the first four em-
ployees at Genentech, Dave Goeddel and 
Dan Yansura, both of whom were part of 
the expression team. 
My lab got involved in solid-phase 
chemical synthesis around 1976 or therea-
bouts. In those days we were very much 
involved in protein - DNA recognition. But 
I had a new graduate student, Mark Mat-
teucci, who wanted to do a project more 
on organic chemistry. So I suggested we 
try and develop a methodology for synthe-
sising DNA on supports. Mark picked up 
this challenge and was focussed on using 
control pore glass and adding nucleotides 
one at a time, and then in collaboration 
with Serge Beaucage who developed as a 
postdoc the phosphoramidite synthans, we 
developed this chemistry for synthesising 
DNA. This is perhaps where I should stop, 
but I had wanted to explain how I got in-
volved in applied molecular genetics and 
from there into Applied Biosystems, but I 
have run out of time. 
 ↠ Bibliography
Caruthers, Marvin and Robert Wells (2011). ‘Har 
Gobind Khorana (1922-2011), Science. 334:1511.
Caruthers, Marvin H. (2012). ‘Gene synthesis with 
H G Khorana’, Resonance. 17:1143–1156.
Caruthers, Marvin H. (2013). ‘The chemical synthe-
sis of DNA/RNA: Our gift to science’, The Jour-
nal of Biological Chemistry. 288:1420–1427.
Caruthers, Marvin H. (2014). ‘Robert Letsinger: 
The father of synthetic DNA chemistry’, Pro-
ceedings of the National Academy of Sciences of 
the United States of America, 111:18098-18099.
Group discussion
Dominic. It seems there is a wide variety of 
ways to synthesise DNA, and it can be hard 
to understand the differences between 
them. Are there ways you could charac-
terise what makes different chemical ap-
proaches distinctive?
Marv. Well to be honest they’re all pret-
ty archaic so I wouldn’t worry about it. 
Dominic. But historians think archaic 
things are pretty cool!
Anonymous 1. I also would push back on 
the question, because everyone is using 
the phosphoramidite chemistry, the only 
difference is what is the hardware to build 
those oligos. 
Lijing. What was considered the signifi-
cance of tackling tour de force questions in 
biology, and how was this kind of activity 
rewarded in biology?
Marv. I have to tell you that molecular 
biologists, biochemists, were not sitting 
around eagerly waiting for someone to 
develop methodologies for DNA synthe-
sis. They couldn’t care less in those days. 
They weren’t interested. For example the 
first Gordon conference I went to in 1975, 
by that time I had worked in Khorana’s lab, 
Letsinger’s lab, and so I was given the re-
sponsibility of reviewing DNA synthesis 
at that time. And so I did. Then that night 
I was sitting around a table having a beer 
and one of the individuals who was attend-
ing that conference, he said “Marv, why 
do you want to learn how to synthesise 
DNA? There’s no reason for it. Sure, Kho-
rana used it to solve the genetic code and 
now he’s made his gene. So what else are 
you going to do with it? Why are you wast-
ing your time learning how to synthesise 
DNA. You’re a bright guy why don’t you 
do something more interesting?” That was 
the mentality. He was not alone. You go out 
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in the world and apart from the aficiona-
dos who were working on DNA chemis-
try and struggling to figure out a way to 
make it, and in those days we had not even 
started on the phosphoramidite method 
yet. There was no interest in DNA chemis-
try at all to speak of, even though Khorana 
was out there preaching how, ‘once we can 
make DNA of a defined sequence we’re go-
ing to be able to do all of these other ap-
plications’. But nobody was really listening 
to him.
Roger. What did you say to him when he 
asked?
Marv. We had started out research in 
Colorado trying to understand how the lac 
repressor interacts with lac operator, and 
lambda phage’s C1 repressor and Cro re-
pressors interact with their binding sites 
on phage lambda. So we were making these 
DNAs synthetically using the old chemis-
tries. So we already knew that there were 
certain applications that you could direct 
your chemistry towards once you had it 
developed in biology. There were a few of 
us around like that, for example Sanger 
in collaboration with a former postdoc-
toral student from Khorana’s lab had syn-
thesised at Cambridge a 12mer that they 
were using for priming sequencing work 
on ϕX174. This was the precursor to all the 
DNA sequencing techniques that we use 
today. So they were using primers in 1975–
76 to develop what they called and present-
ed at the ’77 Gordon conference ‘plus mi-
nus sequencing for DNA.’ They were doing 
that with DNA primers. So if you go and 
look in the right places there were labora-
tories that were starting to use synthetic 
DNA to attack important problems. Not a 
lot but there were some. And if you looked 
at Khorana’s paper you understood why he 
was doing this. As I showed in that quote, 
there were a large number of biological 
problems that required synthetic DNA to 
attack them. But the biological community, 
they just weren’t interested in those days. 
Unless you teach them something, doesn’t 
matter if it’s sequencing or synthesis or 
whatever, once they are taught this they 
say ‘oh yeah that was obvious of course we 
are going to use it’. Until you make it avail-
able it’s like “why are you doing this?”
Alok. The beginning of the solid-phase 
synthesis chemistry, is what was be-
ing called the ‘hardware’. This hardware 
though, might be more seen as a platform 
for integrative buildup. Because the hard-
ware story is about 96 well plates, beads 
don’t give us the next performance curve 
and so on. So the platform unlocked a new 
regime of yield, scale, and variety. Is as-
sembling the platform another example of 
tour de force kinds of project?
Anonymous 1. I think you are getting 
onto something. When you are thinking of 
making a synthetic gene. Building your oli-
gos is only one part of the project. You then 
need to assemble them, fishing out the er-
rors. only 1 in 1000 base pairs going wrong 
is pretty good but it’s not perfect. so you 
still have to clone and pick the perfect 
ones. To do that and scale up to 100,000s, 
you need to automate everything. 
Marv. When we first got this chemis-
try going, all biochemists, biologists, mo-
lecular biologists used it. They were ‘oh 
wow we can make 20mers’. And they were 
very happy with that for at least ten years. 
Honestly it was a few people who started 
going around to, not so much Applied Bio, 
but other companies asking ‘can you make 
100mers because we have some projects 
that require 100mers?’ Then maybe even 
larger, 300mers etc. It was actually these 
people coming and asking for larger com-
pounds. And they were driving things 
along, wanting larger compounds meant 
we needed better yields, driving chemistry 
and instrumentation forward. 
Anonymous 1. And this has an effect on 
price. In 2000 a fully made gene would cost 
$20 a base, now it’s 9 cents a base. Wait a 
few more years and it will be 2 cents a base.
Marv. And people didn’t realise what 
you could do with larger DNAs until you 
could give them access to it.
Alok. Can I make a comparative point 
then? The organism genome platform 
which the Venter Institute is developing, 
which the yeast SC 2.0 Cre-lox system, is a 
wet-ware equivalent to hardware? 
Marv. This is what we’re saying. It’s the 
development of the ability to make longer 
sequences that is leading to the current 
revolution in what you can do with them.
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Jane. Everyone touched on sequencing 
as well as synthesis, could you say more 
about how they are related?
Marv. The current methods of sequenc-
ing require synthetic DNA. And that was 
the way it was for Sanger’s first method. 
You need synthetic DNA to sequence DNA.
Anonymous 1. One pushes the other. It’s 
as with any human endeavour. If you can 
read, that’s good. If you can write, that’s 
good. If you can do both then that’s great. 
At the moment I think synthesis is a little 
bit behind, and we need to catch up the 
writing to the reading. 
Scott. To go back to the era I was talk-
ing about, I described how PCR drove the 
DNA synthesis business, and DNA synthe-
sis drove the ability to do PCR. Ultimately 
what made ABI’s automated sequencer, 
which was the dominant sequencer at 
the time, was the use of a cycling method 
in the chemistry. So you can draw a path 
from synthesis to PCR, PCR people start 
thinking in terms of cycling, and going to a 
cycling version of the chemistry that made 
DNA sequencing robust. 
Dominic. At ABI you mentioned there 
were quite a lot of engineers working 
there, and I was wondering how much bi-
ology they would end up having to learn? 
And could you say more about the relation-
ship between ABI, the Bay area, and uni-
versities? 
Scott. This is true for DNA synthesis, 
but even more so for DNA sequencing. 
DNA sequencing, for example, requires 
marrying expertise in chemistry, fluo-
rescent dyes, molecular biology, optics, 
gel matrices, firmware and software. You 
have an organisation of people who are 
good at their own discipline, and who are 
also learning how to interact with other 
scientist and engineers whose parts of 
the platform touch their own. Engineers 
don’t become experts in chemistry, for ex-
ample, but everyone has to be conversant 
and reasonably knowledgeable in multiple 
domains, and that just comes through in-
teraction with co-workers. As an organi-
sation the ability to develop products in a 
multidisciplinary way becomes a source 
of competitive advantage. A company like 
ABI becomes very skilled over time at in-
tegrating very different technologies to 
achieve a goal. 
You asked about the Bay area. ABI had a 
lot of relationships with folks at Cetus and 
then Roche. It’s complicated, but Perkin-
Elmer who had the market for PCR, bought 
ABI, so when that happened ABI also had 
PCR, at least for the research market.
The universities in the Bay area for some 
reason we never seemed to get along with. 
I don’t know why. We had reasonable re-
lationships with Berkeley and LBL, but 
other than that, we didn’t. Relationships 
with several non-Bay area universities and 
organisations ended up being important, 
though. Thinking now of DNA sequenc-
ing, not DNA synthesis, the key relation-
ship we had was with TIGR (The Institute 
for Genomic Research) and TIGR’s found-
er, Craig Venter. He had the attitude that 
he was going to work with us and not try 
to beat us. Most of the genome sequenc-
ing centres wanted to develop technology 
to avoid buying from us. Craig’s attitude 
seemed to be “My competitors don’t like 
you so I’m going to be your best friend. 
You supply the technology and we’ll focus 
on what we’re good at.”  That, I think, was 
smart. Because of their attitude and ap-
proach to us, TIGR was always an early test 
site, they would get insights into technolo-
gies in development, and they got other 
kinds of preferential treatment.  
Being close to Silicon Valley was re-
ally important, and that classic H-P cul-
ture and attitude, embodied in Sam Eletr, 
Andre Marion and a few other very early 
engineers, was the basis for ABI’s early 
culture.
Marv. It’s worth commenting that what 
really drove the development of modern 
molecular biology and biotechnology was 
the fact that in the mid to late 70s the 
technologies for DNA sequencing, DNA 
synthesis, recombinant DNA technologies, 
cloning, restriction enzyme modification, 
they all came down within a 3,4,5 year 
period. All of them. And that revolutionised 
biology research undoubtedly. And they all 
came together at the same time. If any one 
of them had come up by itself, and then 
only 15 years later another one came along, 
it’s a whole different story. We wouldn’t 
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be sitting here talking about what we’re 
talking about. But they all came together 
at the same time and all at once the world 
exploded with new ways of attacking 
serious and important biological problems. 
What we’re talking about in terms of DNA 
synthesisers and protein sequencers and 
so on, this is all part of that movement, 
because all at once people needed these 
compounds, products, and technology to 
do new state of the art biology. So they 
were pushing the development of these 
techniques. 
A story that you don’t know about Ap-
plied Bio, we actually started that compa-
ny, Lee Hood and I, with these venture cap-
italists as an outgrowth of the group that 
started Amgen. We decided to go forward 
with starting Applied Bio, and we hired 
Sam Eletr. The point is that what Sam 
did, these machines the DNA synthesiser 
and protein sequencer, were in such high 
demand that he went out and he acquired 
contracts from 20 individuals or labs or 
companies, 20 on the DNA synthesiser and 
20 on the protein sequencer and told these 
people ‘OK if you want to be in the queue, 
you’re going to have to pay half the price 
of what we’re going to offer these on the 
market. We haven’t designed them yet, and 
we certainly haven’t manufactured them 
yet. But just to get in the queue you’re go-
ing to have to put down 50% of the selling 
price’. And with that he built the company. 
There was so much demand in those days 
for these machines that he could do that. 
Roger. I was wondering more about cus-
tomer bases, and a broader historical ques-
tion about science funding and changes 
that happened in this revolutionary time 
in the late 70s to early 80s. Who is buying 
most of these products, is it mostly univer-
sities, or private companies, pharmaceuti-
cal companies that have their own research 
institutions?
Marv. All of the above. 
Roger. But who was the bulk?
Scott. There was no bulk. Industrial, 
pharma stuff, biotech, academic, medical 
centres.
Marv. And the manufacturer of the ma-
chines could not keep up with the demand. 
It was that simple.
Dominic. Would you say different things 
to the different customers when you were 
visiting them?
Scott. Not generally. This is an industrial 
sale. Platforms have specifications. You’re 
comparing your product’s performance to 
your competitors’. It always seemed like 
there is a striking amount of animosity 
between companies in the instrumenta-
tion industry. This is probably because po-
tential customers have set budgets, every 
company knows when a given lab intends 
to purchase a DNA synthesiser, the same 
three companies and sales reps will be in-
vited in to make their pitch. One will win 
everything. The others come away with 
nothing. But every customer wanted high 
quality DNA, cheap and fast. So there were 
similar sales points to be made with most 
customers.
Dominic. Would you be able to create 
an example for us, to do with the kinds 
of thing they may say about you, and you 
about them?
Scott. Oh, we would show gel data of our 
very clean oligos. They would argue our 
valve blocks weren’t as good or as impor-
tant as we said they were. They would blow 
out of proportion any reagent problem 
that we might have experienced recently, 
and we would do the same. We’d talk about 
competing instruments’ lack of reliability. 
Fear is an important motivator, especially 
if you’re the market leader. You want to 
create doubt.  You don’t say it directly, but 
it’s understood that if you, the customer, 
buy a competitor’s instrument for $20,000 
less you’re taking an almost personal risk 
that it might not perform. An instrument 
purchase is a highly visible decision within 
a department. So those kinds of arguments 
played a role. But most sales situation in-
volved technical debates about issues that 
to outsiders would seem like pretty modest 
differences.
Marv. Before Scott’s involvement at ABI, 
they had the market for DNA synthesis for 
five or so years, almost entirely exclusively. 
Pretty much in protein sequencing too. So 
they built up a client basis which was basi-
cally everybody in the industry, and then 
the Biosearches of the world and Milligens 
came along.
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Scott. Even when I was there we always 
had roughly 80% of the market share.
Marv. I mean, when we started Applied 
Bio I was pretty upset that we had to cross-
license our patents to Beckman. And Sam 
said ‘Oh don’t worry about it, we’ll be on 
the market and have 80% at least before 
Beckman gets their first prototype built’. 
And of course that’s the way it was. Be-
cause we were a small startup, we weren’t a 
big monolith of a company called Beckman 
instruments. 
Session 3: Objects and epistemics of synthesis
Erin McLeary, Stephanie Lampkin, and Amanda Mahoney
The material heritage of DNA synthesis?
We saw this workshop as a great opportu-
nity to think about, say, if we were to build 
a museum to showcase this history what 
would we collect? What artefacts, what 
stories would we collect, who would we be 
telling them for? We want to work through 
these questions with the group. 
For instance, if GE were to offer us an 
ÄKTA Oligopilot for free for our imaginary 
museum, why might we want to collect it?
Scott. Is it an early DNA synthesiser?
It’s actually a pretty recent one, and I think 
it’s an affordable synthesiser for non-spe-
cialist labs. But if it is not immediately 
familiar to people, is it the kind of object 
the museum would want to collect? What 
about then something like reagent bottles, 
which everyone can recognise? Would we 
want to make space in our museum facility 
to take care of these, and would we want 
the actual chemicals?
Going back to the oligopilot —how do we 
think it would look in an exhibition? Not 
everyone is particularly interested in the 
history of DNA synthesis. What would we 
need to tell a history of it?
Scott. But I don’t know how it fits into 
that story, so I guess I want to know 
what the story is. I’m wondering why it 
came from GE, I’m curious. 
This instrument came into our presenta-
tion simply because I googled ‘DNA syn-
thesis instrumentation’ and this was the 
smallest instrument I could see, I did not 
want to pick a large one. It also was not 
mentioned in any of the studies I have 
read, it wasn’t cited as being used, so I 
chose it as an odd example. It helps illus-
trate the kinds of choices that museums 
have to make.
So one story we might want to tell, would 
be to take the reagent bottles, and the more 
recent machine, and perhaps tell a history 
of automation. 
Alok. GE acquired a company a few 
years ago called Amersham, Amersham 
had the AKTA HPLC system, which got 
extended to compete with ABI to produce 
their synthesiser. So there is a certain his-
tory of taking a platform and growing it 
into an application that has generated its 
own market. So we could see this in a mu-
seum as an example of how technologies 
get combined. 
That’s a great comment first because 
it brings in a corporate history that most 
people would know nothing about.
Alok. Those knobs and that stack of box-
es is well known to people.
Because it’s HPLC? 
Alok. Yes.
So how would we preserve this history?
Alok. Well I would maybe walk along 
Amersham’s HPLC line and then show 
“well the next thing they did was…”
Dominic. And you could trace it back 
to some of the first synthesis machines 
because reworked HPLCs were used 
widely. 
Certainly our museum has a number of 
HLPCs so we could tell that story. 
Marv. Maybe if you contact Applied Bi-
osciences and see if you could get hold 
of one of their first. Then you could find 
someone who was working in a smaller 
lab who couldn’t afford it, and get one 
of their systems that was not really de-
signed as such but was being used to syn-
thesis DNA. After that you might have a 
bunch of arrows going to the applica-
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tions of DNA, such as PCR, and sequenc-
ing, you might want to show a sequencer 
or a little PCR thermocycler, something 
like that. You would then have a little 
story where you start with manual DNA 
synthesis, then going through the Ap-
plied Bio machine and then these appli-
cations that come out of it.
So you’re thinking about sourcing, how to 
find these instruments.
Jeff. A couple of years ago I was at the 
Deutsche Museum in Munich and they 
have a really big collection of these early 
devices. Subsequent to that I went to 
London and they only had one thing on 
display. 
Anonymous 1. One way to make it less 
boring would be to show those four bot-
tles, blue, yellow, pink, and green, those 
are ACTG, through the tube at the end 
comes a long letter of DNA. Putting 
things together on a machine.
So you’re connecting this kind of grey box 
with DNA, which is something most peo-
ple who know a little about science will 
understand. Another thing to notice here 
is that this Oligopilot is connected to a 
computer. So software is vital to using this 
type of equipment, and software is a whole 
other can of worms for both preservation, 
interpretation, and exhibition. How do we 
keep software available for scholars and do 
we share it with visitors? 
Let’s consider an alternative object, 
what about a Controlled Pore Glass Col-
umn? Benefits of this are it is very cheap, 
very small, easy to put on a shelf. 
Marv. So if you look at that Oligopilot, 
that’s a large column for making DNA. 
If you look at these little CPG columns 
where you have a few milligrams of 
Controlled Pore Glass, and in that pre-
vious column you’ve probably got 15-20 
grams. 
How do you get a lay person to a museum 
excited about CPG?
Anonymous 1. The problem there is, in 
chemistry, if you’re a chemist, you go in 
in the morning, you put A together with 
B, and in 5 minutes you have something, 
and then you spend the rest of the day 
purifying. With this, the product, is at-
tached on a bead, so you just filter out 
and save yourself a day of purification. 
This seems like a very good example of 
how the day-to-day work of science has 
changed, and how something as small and 
seemingly mundane as CPG can have a 
huge impact. 
If we were to build a museum to showcase 
this history what would we collect? What 
artefacts, what stories would we collect, 
who would we be telling them for?
I am primarily a historian of the social 
and institutional context of science. What 
I will try and explain is why the Germans 
were not more central to the history of 
DNA synthesis. We mostly hear about the 
UK and the US, but what’s happening with 
the Germans? There are a number of fac-
tors that might help to explain what was 
going on, including the influence of indus-
try, politics, history, and particularly Na-
tional Socialism. They all created a culture 
that was in many ways intended to retard 
the development of this field.
I want to start with the academic-indus-
trial connection in the postwar era. From 
the last third of the nineteenth century the 
Germans were famous for developing a re-
markably successful academic-industrial 
symbiosis, in the dye industry and early 
pharmaceuticals in the form of organic 
compounds. So you had companies like 
Bayer, BASF, and Hoechst, that dominated 
the market for those simple organic com-
pounds back in the early twentieth cen-
tury. After the war, what was going on? I 
looked at a couple of the key German bio-
chemists and their relationship to industry 
in the immediate postwar era. These are 
Richard Kuhn and Adolf Butenandt, both 
of them directors of highly prestigious 
Jeff Johnson 
Factors shaping research in synthetic-chemical biology in the post-
war West-German context (1945–1990): Report on a work in progress
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Fig. 9. Slide highlighting key developments in the organisation of biochemical research in Germany in 
the late twentieth century. Slide produced by Jeff Johnson, who also provides permission for its repro-
duction here. 
Kaiser Wilhelm institutes, the predecessor 
of today’s Max Planck Society, which spon-
sors a total of around 80 institutes in vari-
ous fields. These are focussed on research 
with no obligations to teach. The myth 
goes that all of these people do just basic 
research without attention to applications. 
I have found that in both of these individ-
ual cases, right after the war it was feared 
that they would out-migrate, because the 
conditions in Germany after the war were 
so devastated, and finances so limited that 
they were both entertaining lucrative of-
fers, particularly the United States was a 
possibility. Kuhn could have gone to the 
University of Pennsylvania with a lot of 
funding, and there were companies such 
as Wyeth laboratories, willing to support 
his work on areas of interest to him. For 
example, in regard to the immune factors 
that he was finding in breast milk, Kuhn 
was collaborating with one of the Penn 
professors (Paul György in the medical 
school) who had been an immigrant from 
Germany but had formerly collaborated 
with him in the 1930s before the Nazis took 
over.  In conjunction with his work with 
György, Kuhn had a consulting contract 
with Wyeth (through its parent company, 
American Home Products) until 1955.
The Director of the Bayer pharmaceu-
tical division, Heinrich Hörlein, after the 
war took it as his job to help restore Ger-
man success in biochemistry. So he ar-
ranged industrial subsidies for both Adolf 
Butenandt for very large amounts at the 
time (approximately US $36,000 annu-
ally for several years from 1949), and also 
a smaller subsidy for Kuhn, to ensure that 
they would decline calls from abroad and 
remain in Germany. Both of them also had 
lucrative consulting contracts with indus-
try which in my view may have helped 
keep their attention on the kinds of small 
molecules that could be manufactured in 
these companies, rather than looking at bi-
ologically active molecules which required 
production technologies that we think of 
today as genetic engineering, but which in 
the 50s few Germans were thinking about.
One question we can ask is ‘to what ex-
tent were the Germans really responding 
to the new kinds of technologies that were 
emerging in the United States and else-
where?’ I am not sure that they were, even 
in 1973 when they brought together three 
Max Planck Institutes and made a massive 
complex for biochemistry in Martinsried, 
outside of Munich. They had 11 different 
departments, and that was soon expanded. 
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They were doing all sorts of things, but to 
what extent were they doing the kind of 
fundamental work in recombinant DNA 
and other things that led to Nobel prizes 
elsewhere? I have not been able to look at 
all the data yet, but they seem to be focuss-
ing on other questions, and this was in part 
because the German biochemists had not 
yet been able to make the transition into 
a closer relationship to molecular biology. 
Even the Institute that one would expect 
to be doing this, the Institute for Molecu-
lar Genetics, it had the problem that it 
was a descendent of the 1930s Institute 
for Anthropology, which had been associ-
ated with Nazi racism and experimenta-
tion. The claim I have been hearing is that 
association with chemistry helped these 
groups distance themselves from their sta-
tus as the heirs of Nazi past. So it was in 
many ways a negative motivation to be do-
ing molecular genetics, which had impact 
on their overall funding success and pub-
lic relations.  (Note from September 2018: 
my subsequent work has revealed that the 
leading scientists who were planning the 
Max Planck Institute for Biochemistry at 
Martinsried in the late 1960s discussed the 
possibility of locating the future European 
Molecular Biology Laboratory (EMBL) in 
their complex.  The EMBL’s planners chose 
instead to locate the EMBL in Heidelberg, 
but physically separate from the Max 
Planck Institute for Medical Research.  The 
new Heidelberg EMBL was not completed 
until 1978, however, five years after the 
Martinsried MPI). 
What about contrasting with the kinds 
of devices produced by ABI? If we look at 
a brochure from the MPI for Biochemistry 
in the late 1970s, we see instrumentation 
such as an automated protein sequencer 
from the Department of Protein Chemis-
try, which could sequence peptide chains 
with 50-60 amino acid components. Were 
any of the people there, people who could 
have potentially collaborated with busi-
ness people to found something like ABI 
in Germany? Or were there cultural issues 
that kept them separate? As I said before, 
the industrial people were focussed on 
other kinds of products and were not so 
much interested in trying to develop auto-
mated processes for DNA sequencing and 
synthesis.
What about someone who seems to be 
talking about precisely that kind of bio-
technology industry? Consider the exam-
ple of Ernst-Ludwig Winnacker, who to my 
knowledge was the first person to intro-
duce the term ‘synthetic biology’ into the 
German language, though if you go back to 
1915 you had Emil Fischer, the Nobel prize 
winner, using the term ‘synthetic chemical 
biology’. I asked Winnacker if he had read 
Fischer’s papers, but he didn’t think he had 
been influenced by that. In 1983 Winnacker 
did use the term ‘synthetic biology’ specifi-
cally to describe DNA synthesis. What’s in-
teresting is that he used this in the English 
form in quotation marks, as if he had got it 
from somebody else. We know he studied 
abroad and was actually in Berkley, so I’d 
be interested to know if people in Berkley 
maybe in the 70s were using language like 
synthetic biology at that early point.
Winnacker was the man who as profes-
sor at Munich University founded the LMU 
Gene Centre in Martinsried in 1983-4, ten 
years after the founding of the Max Planck 
Institute there. The difference is that this 
was a university institute and for the first 
time offered a formal connection to allow 
the Max Planck people to have more ac-
cess to students, which would then allow 
them to train the next generation. The 
MPI had groups, called Nachwuchsgrup-
pen (next-generation groups), which were 
for developing young scientists, but I am 
still unclear about their formal connection 
with the university after 1973.  Butenandt 
One question we can ask is ‘to what extent 
were the Germans really responding 
to the new kinds of technologies that 
were emerging in the United States and 
elsewhere?’ I am not sure that they were, 
even in 1973 when they brought together 
three Max Planck Institutes and made 
a massive complex for biochemistry in 
Martinsried
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Robert Smith 
Visions of value and the making of mega-chunks
What kinds of social relations, patterns of 
work and technologies are being imagined 
and configured around DNA synthesis to-
day? Are any of these distinct from the ex-
amples we have heard about so far? To be-
gin to address these questions, I will focus 
on Genome Project Write, a proposal made 
by prominent scientists to synthesise the 
genome of organisms such as mammals, 
including humans.
Methodologically, I am building on 
information drawn from (very early) 
qualitative analysis of publicly available 
documents, technical articles, videos and 
recordings of events and workshops that 
have been run by the Engineering Life 
team, as well as my own notes from par-
ticipation in the GP-write project, most 
recently as a member of the Ethical, Legal 
and Social Issues Advisory Group.
GP-write is a project ‘in the making’. It 
is, arguably, more of a vision or phenom-
and his MPI colleagues taught in the LMU 
medical faculty, because Butenandt was si-
multaneously professor and director of the 
university institute for physiology chemis-
try, as well as director of the MPI.  After 
Butenandt resigned his professorship in 
the LMU to become president of the MPG 
in 1960, however, MPI-LMU relations were 
no longer as close.  The subsequent move to 
the remote location in Martinsried would 
have further disrupted the MPI’s ability to 
train doctoral students who could then re-
produce and further develop new research 
techniques. Winnacker helped to restore 
the connection to the university.
I also wanted to look at the politics. So 
in the early 1980s, just as we have the take 
off of ABI and the biotech industry in the 
US, in Germany they were fighting over 
the dangers of genetic engineering. The 
Green party really took off in 1983, when 
they won their first Bundestag seats, by in-
corporating attacks on genetic engineering 
into their policy. And they got even more 
votes in 1987 following a few important 
publications. One was Benno Müller-Hill’s 
book Tödliche Wissenschaft (Murderous Sci-
ence), in 1984, in which a geneticist who 
had trained in the United States in DNA 
technology exposed the fact that a lot of his 
colleagues were essentially Nazis who had 
covered up their past. This was not good for 
public relations for bioscience in Germany. 
In addition you then had the Bundestag 
Commission, in which Winnacker played 
an active role, on ‘Chances and Risks of 
Gene Technology’. Around the same time 
the Bhopal disaster had a very negative 
impact on the reputation of the chemical 
industry. Ultimately in 1990 came the first 
German law on genetic engineering which 
focussed on the use of a regulatory com-
mission, similar to NIH, but much more 
elaborate. They had to approve every ap-
plication, all done by the Central Com-
mission on Biosafety, for experimentation 
on genetically altered organisms and the 
release of GMOs into production and the 
environment. I think this had a stifling ef-
fect in Germany.
Bayer, for instance, really moved all of 
their active research to the United States. 
They preferred to stay outside of their 
country when working on genetic engi-
neering or genetic diagnoses, in part be-
cause of the PR problems involved.
Marv. There is no question that this 
Green movement in Germany set back 
German science, no question about it. 
You couldn’t go there and learn anything 
new in modern molecular biology, they 
couldn’t do it, because it was against the 
law to do any recombinant research in 
Germany in the 70s, 80s, and 90s. In fact 
all the major pharma and chemical com-
panies set up labs in the US to do their 
research components. They abandoned 
Germany.
I was in the Bayer archive, so was able to 
get their data on the research facility they 
opened in 1988 in West Haven, Connecti-
cut (near Yale University), through their 
American subsidiary Miles Laboratories, 
but I would love to find out about the other 
companies.
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enon than a realised project. A quick look 
on the website and related reporting will 
draw your attention to questions about 
whether the object of synthesis is a human 
genome, whether or not that goal should 
be represented in the name (HGP-write 
or GP-write), about whether this is a sin-
gle project or a consortium of different 
projects and partners, or even whether it 
is a ‘Grand Challenge’. It is so early in the 
making that none of these things are stable 
and it is unclear what actors will coalesce 
or what project will emerge. I want to pro-
pose that there is utility in studying such 
emerging phenomena because it might al-
low us to ask what synthesis is for – what 
kinds of work is required, what kinds of 
social order are produced, what kinds of 
benefits might emerge and for whom, what 
kinds of culture might produce all of these 
things? And, importantly in the workshop 
context, what kinds of synthesis are being 
imagined and put to use? 
At the outset it’s important to acknowl-
edge that there are substantial challenges 
with studying contemporary phenomena 
like this. One that is particularly relevant 
to this context is the notion of a ‘politics of 
novelty’ , which is a rhetorical switch that 
is often present when people talk about 
emerging science and technology. Synthet-
ic biologists are particularly good at this. 
One example is Craig Venter’s unveiling of 
the minimal genome in 2010. He goes to a 
lot of effort to emphasise that this feat was 
‘new’: The team inscribed messages into 
the DNA to make it clear that what you 
see is different. But at other times people 
flip to talk about how what is being done 
is not really new, ‘something we’ve been 
doing for centuries’.  Acknowledging that 
there is a politics of novelty has several 
important consequences. One is that you 
can see immediately that language and the 
way that particular phenomena are framed 
is significant. Another is that this framing 
will vary in relation to different situations 
– the longer view is often adopted under 
situations of (perceived) controversy, for 
instance. A final important consequence is 
that historical scholarship will be vital to 
be able to tease apart contemporary phe-
nomena. 
So, how do we ‘know’ GP-write? What 
kind of histories of GP-write are being 
told? I think two are visible.
 ↠ GP-write as Sc 2.0-2.0. One intui-
tive origin story builds on the lineage of 
genome-engineering projects that precede 
GP-write. These projects are generally told 
in terms of building capacity to synthe-
sise larger and more genetically-complex 
organisms, as in the slide Jane presented. 
The most recent of these projects, Sc 2.0, 
is coming to an end and many of the most 
prominent people involved in Sc 2.0 are 
also involved in the proposed GP-write 
project. And much of the required techni-
cal infrastructure, namely the ability to 
synthesise and construct large chunks of 
DNA is imagined to be foundational for 
any GP-write project.
 ↠ GP-write as HGP-2.0. There are obvi-
ously many links to be drawn between 
the way people talk about GP-write and 
the way they talk about genomics projects 
more-widely.  The synthesis and sequenc-
ing of increasingly complex organisms 
is one example. But the most striking 
parallel that was initially being drawn is 
in an origin story that connects GP-write 
to the Human Genome Project. Much has, 
obviously, been written about this project 
and there are many histories to be told 
of it. And it is therefore worth asking 
which history of the HGP is being told by 
GP-write is a project ‘in the making’. It is, 
arguably, more of a vision or phenomenon 
than a realised project. A quick look on 
the website and related reporting will 
draw your attention to questions about 
whether the object of synthesis is a human 
genome, whether or not that goal should 
be represented in the name (HGP-write 
or GP-write), about whether this is a 
single project or a consortium of different 
projects and partners, or even whether it 
is a ‘Grand Challenge’.
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proponents of GP-write. Here, the domi-
nant narrative is one coupled to so-called 
‘Carlson Curves’. These are images, first 
articulated by Rob Carlson which map the 
cost per base against time for sequencing 
and synthesis of DNA. While sequencing 
has fallen, synthesis remains high. It is 
argued – reasonably –that huge transfor-
mations and societal benefits flow from 
this reduction in cost of sequencing. It 
is claimed that this fall in price per base 
pair was a direct result of the funding of 
‘a’ Human Genome Project; thus, funding 
a second Human Genome Project, one to 
‘write’, will produce similar benefits.
I started by emphasising questions about 
the relationship between GP-write as pro-
posed, the kinds of cultures that it emerges 
from and the kinds of social ordering those 
proposals might do. This line of work em-
phasises that to ‘get synthesis done’ will 
mean enrolling a wide range of people, 
resources and money. Narratives and vi-
sions are central to this process. What can 
be said about these narratives in this vein? 
What are they doing?
One of the first, tentative, things that 
can be said is that these stories is that 
they are doing different, but intertwined, 
things. One origin story blends epistemic, 
organisational and technical histories. It 
helps to make GP-write a credible proposal 
by making it feasible. The other acts as a 
way of conferring value: If the HGP pro-
duced widespread societal benefit by driv-
ing economic reductions in sequencing 
costs, another (H)GP will do the same. But 
this second narrative is arguably one that 
is more about creating a visionary ‘big sci-
ence’ project. Indeed, Andrew Hessel, one 
of the core members of the consortium, 
has been explicit about this in public talks 
and interviews.
A second thing is that they might enrol 
different organisms and in different ways. 
In the first narrative, one that locates 
GP-write as part of a string of genome 
engineering projects, there are many 
organisms that would be credible, obvious 
and scientifically valuable to choose from. 
But in the second, one that confers social 
value and is arguably a much more explicit 
attempt to create a visionary project, the 
human is the necessary organism. Of 
course, societies value these organisms 
differently and the point at which most 
people will have heard about this project 
is in relation to a 2016 meeting, an 
intentional attempt to build momentum 
by coinciding the launch of a Science article 
with an international meeting. Instead, for 
various reasons, it was reported as a ‘secret 
meeting to talk about creating a synthetic 
human genome’.
This reporting ricocheted around the 
world, was described as a plan to create 
designer babies, has been interpreted by 
some in the project as a ‘firestorm’ and has 
had tangible consequences for the pro-
posal. For instance, in the 2017 meeting or-
ganisers were very careful to foreground 
discussion around social, legal, and ethi-
cal issues, with an aim to make sure these 
things were part of the project. More in-
teresting though are the consequences for 
the scientific components and the vision. 
HGP-write has been re-framed as (the ar-
guably broader) GP-write. In this refram-
ing I think what we might be seeing is an 
uneasy blending of the two origin stories 
to produce a third narrative, one which is 
about the value of synthesis more broadly, 
and one which partially rolls back from the 
human. I think, potentially, in this broader 
project there might be space for more di-
verse forms of synthesis than the cloud-
lab highly automated vision attached to 
the HGP-2.0, but I think this may come at 
the expense of a discussion of the value 
of more widely putting DNA synthesis to 
work.
In this reframing I think what we might 
be seeing is an uneasy blending of the two 
origin stories to produce a third narrative, 
one which is about the value of synthesis 
more broadly, and one which partially 
rolls back from the human
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Jane. Could you clarify your very final 
point about the kinds of synthesis?
Robert. The narratives that are being 
told are also attached to different visions 
of doing synthesis. For example, in 
publications of the early Sc 2.0 work, 
which was the creation of one artificial 
chromosome, talks about how the synthesis 
work was done by teams of undergraduates. 
The more recent processes are synthesis, 
using a combination of yeast and machines 
to synthesise very large chunks of DNA. 
The vision of the human synthesis is tied, 
for example by Hessel, to a cloud-based 
foundry model. The work that each of 
these different approaches takes will be 
different and will do different things. Most 
obviously, the UG synthesis approach has 
a pedagogical aspect. But additionally, 
what kinds of questions are answerable 
by building an organism as opposed to a 
genome? One of the things that I want to 
do is separate out the different forms of 
synthesis. What kinds of questions are 
solved by building an organism as opposed 
to a genome.
Anonymous 1. Today companies can 
synthesise the mini-chunks for synthetic 
genomes, that is the easy part. The hard 
part is putting them together into the big 
chromosomes. And then for humans and 
mammalian types the next hard part is to 
methylate all that DNA and then to pack-
age it on histones. So there is more than 
just the synthesis itself. 
Anonymous 1. I understand there is a 
Chinese group that is also trying to get to-
gether, even with the same GP-write name, 
do you know if there is any coordination?
Robert. I don’t know what coordination 
there is but I think that there is a parallel 
geopolitical aspect that is worth unpack-
ing in the narratives around these propos-
als. This kind of thing can happen with 
big flagship projects. So, for instance in 
Europe there is the Human Brain Project. 
But since its launch there have been like 
30 flagship large projects that are all doing 
similar things with very little coordina-
tion. And in America there was the launch 
of the BRAIN initiative, which was a direct 
response to the Human Brain Project.
Anonymous 2. A question for Jeff. I have 
been interested in the agro industry in Ger-
many, and the sources I have been mostly 
looking at are Syngenta, the Swiss com-
pany. I was reading that they had a large 
advantage due to the way the Third Reich 
impacted industry and Syngenta were able 
to fill this gap. So were they perhaps able to 
take over the role that Germany had before 
in Europe?
Jeff. I can’t say too much about what was 
going on in Switzerland. One company cer-
tainly, Hoffman–La Roche, was subsidising 
Adolf Butenandt, so there were some con-
nections between German biochemists and 
the Swiss. I also know Richard Kuhn had 
good relations with Ciba. The Swiss were 
certainly very conscious of what was going 
on in Germany. 
Many of the papers have suggested the 
synergies between technological and sci-
entific innovation, and how these changes 
often make it possible to make brand new 
markets. To what extent can these things 
be seen as determined by technology? My 
sense is that for these markets to develop 
it requires things to come at the right time, 
creating tools for people who may not 
know the possibilities, but somehow when 
the tool is presented they are inspired to 
think more broadly. 
Jody. Robert highlighted this bifurca-
tion of when we say something is new, to 
make an economic market, and when we 
say ‘this is nothing new we have been do-
ing it for thousands of years’. We say those 
simultaneously to two different effects, 
while masking questions we should be ask-
ing. There might also be something deeper, 
regarding the ability to understand histor-
ical precedent, and does it hide the extent 
to which economics is really driving almost 
all of this. What is valuable is often what is 
valuable to the state. If we look at the his-
tory of Justus von Liebig, to take an exam-
ple, there are some interesting historical 
precedents for how we have thought about 
analysis and synthesis, which might help 
us rethink what is going on here in biologi-
cal chemistry. For we might interpret what 
he was doing as chemical, but it was also 
clearly biological. He was also mobilising 
Group discussion
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large numbers of students to get his chem-
istry done, in ways that seem to mirror 
these contemporary biology cases. 
Marv. On the ethics of synthesising ge-
nomes. We can now synthesise the equiva-
lent of a human genome every day. One of 
these days in some place in the world they 
are going to start synthesising a human 
genome, and it will be unlike in the early 
80s when the Asilomar conference was or-
ganised. In those days you dealt with North 
America, Western Europe and Japan and 
that was it. So if you get those countries 
to agree on a set of guidelines, you pretty 
much get all of them. Now if you look at the 
people working on the yeast genome, it’s 
all over the world. So even if one country, 
or one group of countries come up with 
ethical standards for synthesis of the hu-
man genome, how do you deal with that on 
a worldwide basis? It’s an important ques-
tion that I don’t know how to answer. It’s 
tough but we could literally the synthesise 
the DNA for the human genome in one day. 
Jody. One of the questions I was think-
ing about was scale. Is the ethical ques-
tion that you can synthesise so fast, or is it 
about who we think we need to talk to the 
ethics about? 
Jane. There was an international sum-
mit on human genome editing a couple of 
years ago, in 2015, and one of the challenges 
there was how do we have an international 
regulatory system. This conversation is 
happening in those spaces which overlap 
with DNA synthesis.
Jeff. And that conference did produce 
guidelines.
Marv. But with the Asilomar confer-
ence almost every country that was capa-
ble of doing recombinant technologies in 
the early 1980s bought off on the guide-
lines. But just try and do that today. With 
the exception of North Korea you can syn-
thesise a human genome in almost every 
country in the world.
Jeff. That does raise some interesting 
possibilities that someone is potentially 
going to exploit. 
Jane. One of the points of the choice of 
yeast is that it is a very simple organism, 
especially in comparison to the human, 
they have only managed to get three syn-
thetic chromosomes into the cell and the 
cell is quite sick. Anonymous 1 also talked 
about the problem of methylation and the 
chromatin, I don’t think it’s going to be so 
easy. 
Marv. You’re right, it’s not just DNA, 
but still. 
Anonymous 1. There is a biosecurity and 
biosafety angle. So people trying to syn-
thesise Ebola for instance. So if it’s to send 
to a P. O. Box in North Korea, we won’t do 
it, but if it’s to send to the CDC in Atlanta, 
well we do it all the time. You can screen 
and understand intent from looking at the 
sequence. 80% of the companies that make 
DNA from scratch have signed an agree-
ment where they screen every sequence. 
On the question of creating life, people are 
currently struggling with 500 genes. It will 
be a long time before we make a human 
from scratch. What will happen sooner 
is editing of humans. So we need to think 
of somatic mutations as one thing, and be 
much more careful about germline muta-
tion. The whole idea of genetics is that we 
are all different, and we can’t lose that di-
versity. 
Jeff. Is there a set of general principles 
for deciding who gets what and on what 
grounds? There must be a large grey area 
when you are not sure. 
Anonymous 1. There is a government 
defined database of sequences that are 
defined as dangerous. If someone orders 
one of those sequences the synthesiser 
has to screen the user, and if they are 
authorised to use it it is fine. So if they 
had a Professor from Harvard ordering 
smallpox, and they call the Dean and ask 
what this Professor is doing. If they say 
the Professor is working on something 
completely different from smallpox, then 
they would have a question. Most of the 
time, when they get a flag, like a toxin, 
they call them up and talk, and explain it is 
because the thing they ordered was a toxin 
and they go ‘ah, we had no idea, thank 
you I will do something else’. But it’s the 
government database which most people 
agree is the right database. 
Alok. If I could write a sequence for a 
toxin grafting onto a protein, and disguis-
ing the amino acid sequence so that I got 
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1/10th of the scaffold of a harmless protein, 
how would you know?
Anonymous 1. Mostly you are likely to 
lose the activity. So even if you got it, it is 
unlikely to be more dangerous. Companies 
also spend a lot of time talking to govern-
ment agencies, such as the FBI, about the 
spread of biological weapons. What they 
are really worried about is not how some-
one gets the sequence, the hard part is 
making a large amount, and weaponising 
it without killing yourself. It is really only 
states that are large enough to weaponise 
these things. 
Alok. This works for large companies 
like you. But isn’t it the case that as the ma-
chines and chemistry gets cheaper, people 
are going to be able to make more and more 
themselves?
Anonymous 1. It looks to me that DNA 
synthesis is moving towards centralisa-
tion. Less and less people want to have to 
synthesise themselves, they want someone 
to make it all cheaper and faster for them. 
The next pandemic is more likely to come 
from nature. 
Marv. I think when it comes to large ge-
nomes it will always be large companies. 
But when it comes to smallpox you could 
do it with an ABI synthesiser and take a 
month making DNA.
Anonymous 1. But the hard part is to 
weaponise it. How to make a lot of it and 
spray it over a large area. 
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the place of science and technology in our 
lives; to share those tools with our peers; 
and to cultivate and mentor a new genera-
tion of science studies practitioner capable 
of taking these ideas out into the world. 
Since joining CHF—first as a visit-
ing fellow (2005–2007) and then as staff 
(2007–)—Roberts has experimented with 
ways in which we bring the intellectual 
core of science studies into the operations 
of a public-facing institution. Projects 
such as From Inception to Reform: An Oral 
History of the Toxic Substances Control 
Act and Sensing Change provided early 
templates for thinking about how we can 
open new conversations on topics that 
often seem impenetrable, hidden, or too 
politically charged. More recent and ongo-
ing projects, such as REACH Ambler, have 
taken these lessons and continued to ex-
periment with ways in which histories of 
the present provide platforms for speaking 
about possible futures. 
.
Robert Smith
Rob works in the field 
of science and technol-
ogy studies. His work 
explores the social and 
ethical dimensions of 
the biosciences, primarily in relation to 
science policy, research funding and labo-
ratory science. As part of the Flowers Con-
sortium (at King’s College London) and the 
Engineering Life project (at the University 
of Edinburgh) he is currently research-
ing attempts to automate the practice of 
synthetic biology, the ways that interdis-
ciplinarity and collaborations happen — 
especially between the social and natural 
sciences — and notions of value within re-
search agenda setting, particularly in the 
context of ‘grand societal challenges’.
Alok Srivastava
Alok is an independent 
scholar working in so-
ciology, philosophy, and 
history of science in San 
Francisco. He obtained 
his Ph.D. in Biochemistry and Biophysics 
from MIT. His Ph.D. research focused on 
studying the structural aspects of protein 
folding as it pertains to engineering pro-
teins for stability and function. He has 
been working in the biotechnology indus-
try and was involved in projects developing 
an ultra-sensitive bioassay platform based 
on Bio-Micro-Electro-Mechanical Systems 
(Bio-MEMs) employing acoustic sensors, 
and a discovery platform for ultra-specific 
biomarkers for early detection of cancers 
based on aberrant Post-Translational Pro-
tein Modifications proteins in cancer cells. 
His current project in industry involves 
building an online platform for collabora-
tive problem solving to support clinical 
treatment planning for uncommon cases 
in cancer.
Dr. Srivastava’s research interests in so-
ciology of science focuses on the processes 
of change in scientific capacities of labora-
tories and research communities engaged 
in multi-disciplinary and integrative 
projects. He is studying these problems 
through a series of historical case studies 
in chemistry, biochemistry, molecular bi-
ology, synthetic biology, integrative medi-
cine and related areas.
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Annex: Workshop Documentation
• How could biologists specify and create 
DNA sequences before the chemical ap-
proach was an option? What practices did 
this involve?
• How have biological, chemical, and en-
gineering knowledge contributed to the 
development of DNA synthesis and its 
expansion into an industry? Not just their 
knowledge involved?
• Did the chemical synthesis of DNA teach 
biologists/biochemists anything about bi-
ological phenomena, for example, about 
synthesis processes within organisms?
• Who/what were the first companies or 
organisations to offer synthesis to order, 
or offer synthesis machines?
• When is DNA a tool? A product? A puzzle?
• How could a museum collect the history 
of DNA synthesis?
• What are the relations between organ-
isms in receipt of synthesised DNA and 
those inheriting DNA through biological 
reproduction, or receiving it from anoth-
er organism?
• How is synthesis influencing the biologi-
cal sciences? Or the biological sciences 
influencing synthesis?
• What are the limitations for synthesis?
• What new social relations does the capac-
ity for gene and genome synthesis pro-
duce?
• How are synthesised nucleotides used in 
research, be it for scientific or industrial 
purposes?
Questions that inspired the workshop and which 
were circulated to participants
Programme
Coffee and registration 
Dominic Berry: Welcome and introduction 
Session 1: Whole genomes/organisms 
(two 20 minute talks and 30 minute discussion)
Alok Srivastava & Elihu M. Gerson
Synthesis of Viable Genomes and Organisms: Understanding Wholes
Jane Calvert 
Synthetic yeast: a tale of sixteen synthetic chromosomes
Questions and discussion
Coffee
Session 2: Extending synthesis
(two 20 minute talks and 50 minute discussion)
L. Scott Cole 
Selling DNA Synthesis: Applied Biosystems’ DNA Synthesis Business 
from 1989–1992
Marvin H. Carruthers 
The Chemical Synthesis of DNA, RNA, and Certain Analogs
Questions and discussion
9:30–10:00
10:00–10:20
10:20–10:40
10:40–11:00
11:00–11:30
11:20–11:45
11:45–12:05
12:05–12:25
12:25–13:15
Tuesday, 28th November. Venue: CHF.
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Lunch
Erin McLeary, Stephanie Lampkin, Amanda Mahoney
The material heritage of DNA synthesis?
Session 3: Epistemics of synthesis
Jeff Johnson 
Factors shaping research in synthetic-chemical biology in the postwar 
West-German context (1945–1990): Report on a work in progress
Robert Smith
Visions of value and the making of mega-chunks
Questions and discussion
Wrap up and final thoughts
13:15–14:00
14:00–14:20
14:20-14:40
14:40-15:00
15:00-15:30
15:30–...
Submitted abstracts
Jane Calvert
Synthetic yeast: a tale of sixteen synthetic 
chromosomes
The synthetic yeast project is an international ef-
fort to comprehensively re-design and construct 
the genome of the yeast species Saccharomyces 
cerevisiae wholly from laboratory-synthesised 
DNA. The dual aims of the project are to learn 
more about yeast biology and to develop improved 
yeast strains for industrial use. Many changes are 
being made to the genome to further these aims, 
including removing repetitive regions of DNA, 
constructing a ‘neochromosome’, and building in 
the ability to evolve the yeast on demand. Ques-
tions arise about whether the completed synthetic 
yeast—known as Saccharomyces cerevisiae 2.0 —will 
be a different species from the wild-type.
Unlike other branches of synthetic biology, 
which focus on building discrete genes or genetic 
circuits, the synthetic yeast project is an example 
of construction at the whole genome scale. It fol-
lows in the steps of previous viral and bacterial 
whole genome synthesis projects, but is approxi-
mately an order of magnitude larger. The size of 
the project requires an internationally distributed 
effort, involving the coordinated activity of eleven 
labs across North America, Europe, China, Singa-
pore, and Australia. The sixteen chromosomes are 
distributed around this international consortium.
This presentation draws on interviews with 
members of the project consortium, and visits to 
the different laboratories. Although all the syn-
thetic chromosomes are designed at the PI’s labo-
ratory in NYU (with the exception of the neochro-
mosome), the individual laboratories have pursed 
different synthesis and assembly strategies. For 
example, in Tianjin, China, one of the chromo-
somes was entirely synthesized by an undergrad-
uate class as part of a ‘build-a-genome’ course. 
These different chromosomes also have different 
qualities and characteristics, and the scientists 
often refer to these to identify their ‘favourite’ 
chromosome. In addition, several of the laborato-
ries are starting to design their own novel, bespoke 
chromosomes.
Some hope that the synthetic yeast project 
marks the start of a new era of whole genome 
‘writing’ projects, which will involve the synthesis 
of the genomes of a range of species, including the 
human. Whether or not this initiative progresses 
as planned, I argue that whole genome synthesis 
projects would benefit from increased sociological, 
historical and philosophical attention.
Marvin H. Caruthers
The Chemical Synthesis of DNA, RNA, and Cer-
tain Analogs
The chemical synthesis of DNA/RNA dates from 
the mid 1950s in the laboratory of Sir Alexander 
Todd. Shortly thereafter Gobind Khorana pio-
neered the use of synthetic DNA/RNA for solving 
various biological problems such as the genetic 
code and the use of sequence defined oligonucle-
otides as templates for DNA/RNA polymerases 
and to solve biological problems including the 
synthesis of genes and studies on how proteins 
recognize DNA/RNA. Following this initial work, 
Bob Letsinger developed an entirely new synthe-
sis methodology that was used in the initial DNA 
sequencing methods from Sanger’s laboratory and 
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for synthesizing the human insulin and human 
growth hormone genes —developments that led 
directly to the establishment of the biotechnology 
industry. A brief review of these methodologies 
and some of the lessons learned about pioneering 
basic research will be discussed.
From 1977–1982 Professor Marvin Caruthers 
developed the use of nucleoside phosphoramidites 
as stable monomers for the solid phase synthesis 
of DNA and RNA. This ground-breaking chemis-
try was far superior to anything at that time and, 
even today some 35–40 years later, remains the 
methodology of choice for synthesizing DNA/
RNA. Its chemical accuracy has enabled it to be de-
ployed from the micromolar scale of DNA oligomer 
preparation for various clinical applications down 
to microdot, nano-scale chemistry that is used for 
numerous biological, biochemical, diagnostic, and 
chemical applications. Currently and in collabo-
ration with Agilent, Prof. Caruthers has adapted 
this chemistry to the synthesis of DNA on glass 
chips (244,000 DNA segments per chip at 200-300 
nucleotides in length / segment). For many differ-
ent research applications, this on-chip process is 
performed at the level of 6 to 20 billion nucleotide 
condensations per day (the equivalent of several 
human genomes of 3 billion base pairs). Moreover, 
this work is now at the core of current DNA and 
RNA sequencing technologies. Modern biology 
could not have achieved its explosion of discovery 
over the last 40 years without the near-flawless 
phosphorus chemistry that the phosphoramidite 
methodologies have delivered to science and tech-
nology.
Notwithstanding the tremendous success of 
this basic phosphorus chemistry, Prof. Caruthers 
continues to develop the chemistry of key P(III) 
species for new purposes. If time permits, the syn-
thesis of a new analog called thiomorpholino DNA 
will be discussed and certain initial biological re-
sults will be presented.
L. Scott Cole
Selling DNA Synthesis: Applied Biosystems’ 
DNA Synthesis Business from 1989–1992
From its founding in 1981 until its acquisition in 
2008, Applied Biosystems’ Incorporated (ABI, Fos-
ter City, CA) was the leading supplier of instrument 
and reagent platforms for life science research. 
In 1985, the company introduced the Model 380A 
DNA Synthesizer, its first commercial platform 
for phosphoramidite-based DNA synthesis. Over 
the next several years, a combination of improve-
ments in both DNA synthesis instrumentation and 
reagents enabled the company to achieve a domi-
nant position in the DNA synthesis market world-
wide. In this talk I will provide a commercial per-
spective on oligonucleotide synthesis based on my 
experience as Product Manager for DNA synthesis 
at ABI from 1989 through 1992. This was a time at 
which the need for synthetic oligonucleotides was 
growing rapidly, primarily based on rapid growth 
in the use of the Polymerase Chain Reaction (PCR). 
I will discuss ABI’s entry into the DNA synthesis 
market, the competitive landscape at the time, how 
the company’s DNA synthesis team was structured 
and how it operated, and I’ll provide a sense of 
ABI’s corporate culture at the time.
Jeff Johnson
Factors shaping research in synthetic-chemical 
biology in the postwar West-German context 
(1945–1990): Report on a work in progress
The purpose of the present paper is to examine 
some of the factors affecting the political, institu-
tional, and scientific context of research in syn-
thetic-chemical biology in postwar West Germany, 
1945–1990. It is well-known that the West-Germans 
were considerably behind their colleagues in other 
western nations (particularly Britain, France, and 
the United States) in taking up the challenges and 
opportunities posed by the postwar development 
of molecular biology and the various technologies 
leading to genetic engineering. In some ways this 
is a surprising phenomenon, because at least until 
the 1930s the Germans had been among the world 
leaders in a field that I will designate as synthetic-
chemical biology, using the terminology of Emil 
Fischer in 1915; unaware of Fischer’s earlier termi-
nology, Ernst-Ludwig Winnacker introduced the 
term “synthetic biology” into the German context 
in 1983, applying it specifically to the synthesis of 
genes.
Obviously one of the critical factors affecting 
the German situation was the impact of National 
Socialism, not only its purges of German scientific 
institutions but also the destruction brought about 
by its failed war of conquest. Beyond these factors 
were others inherent in the post-Nazi German con-
text of the mid-20th century. In this paper, I would 
like to examine some of these factors by looking at 
specific examples of German organic chemists and 
biochemists in their institutional contexts, consid-
ering both the elite Max Planck Institutes (such 
as the MPI for Biochemistry in Munich and the 
MPI for Medical Research in Heidelberg) as well 
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as university institutes in related fields. I am also 
interested in considering the extent to which the 
German chemical and pharmaceutical industry in 
the postwar era continued its decades-old tradition 
of promoting close academic-industrial collabora-
tion. Finally, I would like to examine the political 
context, including German debates over the ethics 
and risks of biotechnology and genetic engineer-
ing during the 1980s. When Winnacker introduced 
the term synthetic biology, the German debate was 
just beginning; it culminated in 1990 in the first 
German Genetic Engineering Law, whose origin 
should be seen in the light of the historical and cul-
tural burden of Nazi atrocities.
SHI Curatorial team
The material heritage of DNA synthesis?
What is the material heritage of DNA synthesis? 
In this interactive session, workshop attendees 
and CHF museum staff will collectively imagine a 
museum of DNA synthesis. What artifacts would 
be displayed in this museum? What stories would 
those artifacts tell? For what audiences should 
those stories be told? And what would it take to 
move from an imagined museum to a collecting 
initiative that acquires and preserves the material 
heritage of DNA synthesis?
Robert Smith
Visions of value and the making of mega-
chunks
This workshop addresses DNA synthesis as his-
toriographically neglected. Today DNA synthesis 
seems to be going through somewhat of a resur-
gence. For instance, in Britain the UK taxpayer has 
indirectly contributed more than £150m to syn-
thetic biology projects. Included in this figure is 
roughly £17,528,700.00 towards six so-called ‘DNA 
foundries’. In the United States the Broad Institute 
has recently been awarded a five-year, US$32 mil-
lion contract from the Defense Advanced Research 
Projects Agency (DARPA) to design, fabricate, and 
test large DNA sequences at scale. Similarly, and 
with much bombast, a team with George Church, 
Jef Boeke and Andrew Hessel have proposed a 
new grand challenge—the synthesis of large scale 
chunks of DNA—accessible for the modest price 
tag of £500m.
The rhetoric surrounding many of these invest-
ments is unsurprising to anyone following new 
and emerging forms of knowledge production and 
technology creation. And yet at the same time, past 
work has shown that such claims are not isolated 
or detached from reality. Perhaps the most blunt 
example one can give is to point to the fact that 
claims about future value are excellent ways to en-
rol people into a project. We should then pay ana-
lytic attention to claims about the purpose of do-
ing DNA synthesis and the ways that they are built 
into websites of objects, people, places, and values. 
In this talk I will take a first pass at doing just 
that. To do so I will draw on early reflections from 
on-going documentary work and observational 
material at synthetic biology conferences around 
the world. I will examine the cultures that such 
narratives claim to produce, the values that they 
embed and the significance of these things, both 
for life as we know it and for the social and human 
sciences as we relate to the natural and physical 
sciences.
Alok Srivastava & Elihu M. Gerson
Synthesis of Viable Genomes and Organisms: 
Understanding Wholes
This paper explores some issues raised by the 
synthesis of complete functional units – genes, 
pathways, biochemical complexes and the exten-
sion of this work to the making of autonomous 
wholes such as viable genomes and cells. Synthe-
sis experiments generate a unique kind of un-
derstanding, achieved by de-composing and re-
composing functional units. Such efforts directly 
address the descriptive and interactional complex-
ities of biological systems and their constitutive 
mechanisms.
Synthesis experiments interpret mechanisms 
by demonstrating that articulated parts, refined 
and reassembled, behave as we expect them to. 
Synthesis experiments reveal and mark gaps be-
tween the explanations and manipulative results, 
and help specify the efforts to fill these gaps.
In synthesis experiments, scientists must learn 
to deal with incomplete systems that are not (yet) 
complete or viable. Laboratory procedures act as 
scaffolds that provide functional support for in-
termediate stages of construction. For example, 
a database containing the sequence of bases of a 
full bacterial genome keeps the order and content 
of the organism’s genome while it is being chemi-
cally synthesized and biochemically assembled. 
This computer file thus functions simultaneously 
as a scaffold for the genome under construction, 
and as an important part of the laboratory’s work 
organization.
The laboratory thus acts in place of the cell, sup-
porting and enabling the assembly process by de-
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veloping and deploying a set of protocols that spec-
ify needed resources and context to the incomplete 
system. These protocols also serve as bookkeeping 
devices that mark the parts of explanation(s) that 
are not yet realized as manipulation capacities.
Synthesis thus operates by mapping and track-
ing the relationships between de-composition 
procedures and corresponding re-composition 
procedures. Making and testing complete func-
tional units enforces a reconciliation among the 
different groups of procedures. It is useful to un-
derstand synthesis experiments as explaining 
biological systems by carrying out re-composition 
experiments corresponding to de-composition ex-
periments. A particular kind of understanding is 
achieved by these full cycles of de-composition and 
re-composition experiments of functional units 
and autonomous wholes that directly address the 
descriptive and interactional complexities of bio-
logical systems and their possible mechanisms.
